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Melissa Noel-Castro, Ph.D.
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Ethanol exposure during synaptogenesis can result in brain and behavior
neurotoxic defects referred to as fetal alcohol syndrome (FAS). Since tissue
plasminogen activator (tPA) has been implicated in mediating excitotoxic
neurodegeneration we subjected neonatal WT and tPA-/- to an acute ethanol
paradigm that serves as a model of FAS.

We observed persistent

upregulation of tPA and extensive neurodegeneration after ethanol in the
forebrain of WT. However, tPA-/- mice were protected from neuronal death,
suggesting tPA mediates ethanol-induced neurodegeneration and FAS in
mice. Commensurate with neuronal death, we observed ethanol-induced
cognitive impairments in adult WT, but not tPA-/- mice. To understand how
ethanol affects tPA we subjected mice to drugs that mimic the actions of
ethanol in the brain. tPA-/- mice were protected from neurodegeneration after
treatment with NMDA-R antagonist, but not after GABAA-agonist,
suggesting tPA acts via an NMDA-R mediated mechanism.

We also

investigated the role of the tPA inhibitor plasminogen activator inhibitor-1

(PAI-1) in FAS.

We observed PAI-1-/- mice were more vulnerable to

ethanol-induced neurodegeneration than WT mice. In addition, we found
that

tPA-/-:PAI-1+/-

mice

treated

with

ethanol

showed

increased

neurodegeneration than tPA-/- mice. These results suggest PAI-1 is involved
in neuronal survival after ethanol. Finally, we explored the role of tPA in
hippocampal synaptic plasticity after chronic stress. We restrained WT,
tPA-/-, and PAI-1-/- mice for 21 days. We found chronic stress increased tPA
activity in WT and PAI-1-/- mice. Stress greatly reduced PAI-1 below
baseline levels in WT mice. These stress-induced changes in tPA activity
and PAI-1 resulted in decreased contextual fear conditioning in WT and
PAI-1-/- mice. Chronic stress did not affect contextual learning in the tPA-/mice. These results suggest tPA is necessary for the synaptic plasticity
cascade that causes cognitive deficits after chronic stress exposure.
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thesis

iii

ACKNOWLEDGEMENTS
I wish to thank my incredible advisor, Dr. Sidney Strickland, for his constant
support and guidance during my time at Rockefeller.

I also thank my

wonderful thesis committee members, Dr. Bruce McEwen and Dr. MaryJeanne Kreek for their invaluable mentorship. Also, I thank Dr. Daniel
Lawrence for taking the time to serve as the external member of my thesis
committee.
Finally, I wish to thank the members of the Strickland Laboratory, in
particular Dr. Karen Barker-Carlson for her critical reading and helpful
discussions regarding my thesis. I also thank Drs. Rajani Maiya and Erin
Norris for their great scientific discussions throughout my thesis research.

iv

TABLE OF CONTENTS

Page

Chapter 1: Introduction
1.1 Fetal alcohol syndrome

1-4

1.2 Tissue-type plasminogen activator in CNS physiology

4-5

1.3 NMDA-R

6-9

1.4 NMDA-R-dependent signaling in FAS: nNOS and
neurotrophic factors

10-13

1.5 Plasminogen activator inhibitor type 1 (PAI-1) in CNS
physiology

14-16

1.6 Chronic stress effects on hippocampal-dependent learning

16-18

Chapter 2. Materials and Methods
2.1 Animals

19

2.2 Polymerase chain reaction (PCR)

19

2.3 Materials

20

2.4 Acute ethanol treatment

20

2.5 tPA in-gel zymography

21

2.6 in situ zymography

21-22

2.7 Fluorescent in situ zymography

22

2.8 Immunoprecipitation and western blotting

22-23

2.9 Antibodies

24

2.10 Cleaved caspase-3 immunostaining

24-25

2.11 tPA Immunostaining

25

2.12 PAI-1 Enzyme-Linked Immuno Sorbent Assay (ELISA)

26

2.13 Fluoro-Jade B staining

26-27

v

2.14 Fluoro-Jade B quantitation and analysis

27

2.15 Blood ethanol leves determination

28

2.16 Evans Blue extravasation

28

2.17 Restraint stress

28-29

2.18 Fear conditioning

29-30

2.19 Statistical analyses

30

Chapter 3. Results
3.1 Ethanol treatment increased neuronal-associated
tPA activity in perinatal mouse pups

31-34

3.2 tPA upregulation corresponds to increased apoptotic
neurodegeneration after ethanol

35-45

3.3 tPA induction of neurodegeneration is
plasminogen-independent

46-48

3.4 tPA induction of neurodegeneration is independent
of its proteolytic activity

49-54

3.5 tPA promotes neurodegeneration by downregulating
neurotrophic factor expression following ethanol
ingestion

55-56

3.6 Ethanol does not suppress synaptic activity markers in
the tPA-/- mice

57-59

3.7 tPA promotes neurodegeneration via the NMDA-R

60-65

3.8 Ethanol differentially modulates the NMDA-R in
WT and tPA-/- mice

66-71

3.9 tPA-deficient mice were protected form cognitive
defects induced by early postnatal ethanol treatment

vi

72-73

3.10 Ethanol treatment increased neuronal-associated
tPA activity in perinatal PAI-1-/- mouse pups
3.11 Ethanol modulates PAI-1 in a tPA-independent manner

74
74-76

3.12 PAI-1-deficient pups are more vulnerable to
ethanol-induced neurodegeneration

77-81

3.13 tPA promotes ethanol-induced neurodegeneration in
PAI-1-/- mice

81-83

3.14 Ethanol decreased nNOS expression in PAI-1-/- mice

84-85

3.15 PAI-1 promotes neuronal survival and tPA promotes
neuronal death after ethanol treatment

86-87

3.16 Chronic stress increases hippocampal tPA activity
in WT and PAI-1-deficient adult mice

88-89

3.17 Chronic stress decreases hippocampal PAI-1 levels in
WT mice

90

3.18 Chronic stress decreases fear conditioning in
WT and PAI-1-/- mice, but not in tPA-/-

91-92

Chapter 4. Discussion
4.1 Ethanol and neurotoxicity in a murine model of FAS

93-94

4.2 Ethanol modulates tPA activity and PAI-1 expression in
WT pups

94-95

4.3 tPA-/- mice are resistant to ethanol-induced
apoptotic signaling and neurodegeneration

95-96

4.4 tPA-induced neurodegeneration after ethanol
is independent of proteolysis and plasmin production

96-97

4.5 tPA-mediated ethanol-induced neurodegeneration occurs
via the NMDA-R

98-102
vii

4.6 tPA-/- mice have increased neurotrophic factor
expression

102

4.7 Neonatal ethanol-induced neurodegeneration
leads to adult cognitive impairments

103

4.8 tPA is a key regulator of ethanol-induced
neurodegeneration and FAS development

103-106

4.9 Ethanol treatment increased neuronal-associated
tPA activity in perinatal PAI-1-/- mouse pups

106-107

4.10 Ethanol modulates PAI-1 in a tPA-independent
manner

107-108

4.11 tPA promotes ethanol-induced neurodegeneration
in PAI-1-/- mice

108-110

4.12 Ethanol decreased nNOS expression in PAI-1-/- mice

110-111

4.13 PAI-1 promotes neuronal survival and tPA promotes
neuronal death after ethanol treatment

112-114

4.14 Ethanol exposure of the immature murine brain can
lead to learning deficits that are characteristic of FAS
in humans

115

4.15 Chronic stress regulates hippocampal-dependent
behavior via modulation of the tPA/PAI-1 system

References

116-118
119-145

viii

LIST OF FIGURES

Page

Figure 1. Ethanol treatment increased neuronal-associated
tPA activity in perinatal mouse pups

33

Figure 2. Ethanol induces neurodegeneration in
the cortex of WT mice, but not tPA-/-

37

Figure 3. Ethanol induces neurodegeneration in the
thalamus of WT mice, but not tPA-/-

38

Figure 4. Ethanol induces attenuated neurodegeneration
in the hippocampus of WT mice, but not tPA-/-

39

Figure 5. Blood ethanol concentrations are similar
in WT and tPA-/- pups

40

Figure 6. Ethanol induces caspase-3 activation and
cytochrome c immunoreactivity in WT, but not
tPA-/- mice

42

Figure 7. tPA-STOP attenuates ethanol-induced
neurodegeneration in WT mice

44

Figure 8. WT mice, but not tPA-/-, show increased
CD11b immunoreactivity after ethanol
ix

47

Figure 9. tPA-mediated neurodegeneration after ethanol is
plasmin-independent

48

Figure 10. S481A tPA partially restores ethanol-induced
neurodegeneration in the tPA-/- mouse

51

Figure 11. The P7 mouse blood brain barrier is
permeable to Evans Blue extravasation

54

Figure 12. Neurotrophic factors are increased in the
tPA-/- forebrain 24 hrs after ethanol

56

Figure 13. Ethanol does not suppress synaptic activity
markers in the tPA-/- mice

59

Figure 14. tPA promotes neurodegeneration via the NMDA-R

61

Figure 15. tPA-/- mice are resistant to NR2B-mediated
neuronal death

64

Figure 16. Ethanol differentially modulates the NMDA-R
in WT and tPA-/- mice

67

Figure 17. Ethanol modulates ß-adaptin association to
NR2B in WT, but not tPA-/- mice

x

71

Figure 18. Neonatal exposure to ethanol induces learning and
memory deficits in WT, but not tPA-/- mice

73

Figure 19. Ethanol treatment increased tPA activity in
perinatal PAI-1-/- mouse pups, and modulated PAI-1
in a tPA-independent manner

76

Figure 20. PAI-1-deficient pups were more vulnerable to
ethanol-induced neurodegeneration in the cortex

79

Figure 21. PAI-1-deficient pups were more vulnerable to
ethanol-induced neurodegeneration in the thalamus

80

Figure 22. Blood ethanol concentrations are similar in
WT and PAI-1-/-

81

Figure 23. tPA promotes ethanol-induced neurodegeneration
in PAI-1-/- mice

83

Figure 24. Ethanol decreased nNOS expression in PAI-1-/- mice

84

Figure 25. PAI-1 promotes neuronal survival and tPA
promotes neuronal death after ethanol treatment

87

Figure 26. Chronic stress increases hippocampal tPA
activity in WT and PAI-1-/- mice

xi

89

Figure 27. Chronic stress decreased hippocampal PAI-1
levels in WT mice

90

Figure 28. Chronic restraint impairs contextual fear
conditioning in WT and PAI-1-/- mice but not tPA-/-

92

Figure 29. Model representing ethanol modulation of tPA
and PAI-1 in the neonatal brain.

xii

113

CHAPTER 1: INTRODUCTION
1.1 Fetal alcohol syndrome
Ethanol exposure during synaptogenesis can result in neurotoxic brain
defects referred to as fetal alcohol syndrome (FAS). The syndrome can lead
to myriad of mental health problems including cognitive deficits, mental
retardation, psychosis, depression, hyperactivity, and schizophrenia (Jones
and Smith, 1973; Swayze et al, 1977; Kerns et al, 1977; Clarren and Smith,
1978; Sulik et al, 1981; Famy et al, 1998). According to the Center for
Disease Control and Prevention, FAS is the leading preventable cause of
mental retardation in the U.S. with a rate of 1 case developing the disorder
for every 500 live births. There is no cure for FAS, yet the syndrome afflicts
more babies born every year in the United States than the combined total of
infants born with Down’s syndrome, muscular dystrophy, and HIV
combined.
Following the ethanol exposure that leads to FAS, there is significant
brain mass loss and widespread neuronal death. The developing brain is
more

vulnerable

to

ethanol-induced

neurodegeneration

during

synaptogenesis (West, 1987; Dobbing and Sands, 1979; Goodlet and West,
1992), an activity-dependent process. Rats exposed to ethanol during the
synaptogenesis period at postnatal day 7 are vulnerable to ethanol-induced
1

neuronal death, while animals exposed to the same dose at postnatal day 21,
when synaptogenesis has ended, are resistant to neurodegeneration (Heaton
et al, 2003).
Ethanol reduces neuronal activity through a dual mechanism: antagonism
of the N-Methyl-D-Aspartate receptor (NMDA-R) and potentiation of the
gamma amino butyric acid type A receptor (GABAA-R) (Hoffman et al,
1989; Lovinger et al, 1989; Harris et al, 1995; Ikonomidou et al, 1999 and
2000).

Drugs that mimic ethanol via inhibition of NMDA-R or

hyperactivation of GABAA-R lead to a pattern of neurodegeneration that
when composited together resemble what is observed after exposure to
ethanol in neonatal rats (Ikonomidou et al, 1999 and 2000).
During synaptogenesis multiple subsets of CNS neurons depend on
depolarization-induced elevation of intracellular calcium and the subsequent
activation of multiple signaling cascades to survive. NMDA-R blockade by
ethanol can inhibit these survival signals (Mennerick and Zorumski, 2000).
A single large dose of ethanol administered during synaptogenesis leads to
widespread neurodegeneration, and subsequent behavioral impairments in
cognitive tasks in rodents that mimic those seen in humans with FAS
(Ikonomidou et al, 2000; Dikranian et al, 2001, Maas et al, 2005; Olney et
al, 2002; Ieraci and Herrera, 2006).
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Furthermore, mice deficient in adenylyl cyclases 1 and 8, which are crucial
components of the cAMP signal transduction pathway and are directly
stimulated

by

calcium,

are

more

vulnerable

to

ethanol-induced

neurodegeneration (Maas et al, 2005).
Neuronal death is dependent on the activation of the key apoptotic
protease caspase-3 (Olney et al, 2002), and entails the release of cytochrome
c from the mitochondrial membrane (Young et al, 2003). Treatment with
nicotinamide following ethanol exposure can diminish activation of the
apoptotic cascade, reduce neurodegeneration, and consequently prevent
ethanol-induced behavioral impairments such as hyper-activity and
decreased contextual fear conditioning in mice (Ieraci and Herrera, 2006).
Neurodegeneration is observed most prominently in the cerebral cortex,
thalamus, hippocampus, and cerebellum in rodents (Ikonomidou et al, 2000;
Dikranian et al, 2005). The improper development of neural circuits due to
ethanol-induced mass deletion of neuronal populations in these brain regions
is thought to underlie the deficits in learning, memory, and locomotion
observed in adult animals in a model of FAS. Furthermore, identification of
the mechanisms by which ethanol induces neurodegeneration in the
developing brain is relevant to other clinical scenarios, including pediatric

3

anesthesia, antiepileptic therapy, and exposure of the immature brain to
other NMDA-R antagonist drugs or GABAA-R agonists.

1.2 Tissue-type plasminogen activator in CNS physiology
Tissue plasminogen activator (tPA) is a highly specific serine protease
expressed in the vasculature where it initiates fibrinolysis via activation of
the inactive zymogen plasminogen into plasmin (Carmeliet et al, 1994;
Collen D, 1999). tPA is also expressed in the central nervous system (CNS),
in neurons and microglia, where it plays multiple extravascular roles, both
plasminogen dependent and independent (for a reviews see Melchor and
Strickland, 2005; Benchenane et al, 2004). In neurons, tPA is stored in
dense-core vesicles, transported to axon terminals, and released into the
extracellular space in a regulated manner (Gualandris et al, 1996). tPA
activity in the CNS is specifically regulated by the serine protease inhibitors
(serpins) plasminogen activator inhibitor-1 (PAI-1) and neuroserpin.
The tPA/plasmin system is involved in neuronal growth cone penetration
(Krystosek and Seeds, 1981), and migration of cerebellar granule neurons
during development (Friedman and Seeds, 1995). tPA is also critical in
synaptic plasticity processes that are necessary for learning and memory and
long-term potentiation (LTP) (Qian et al, 1993; Seeds et al 1995; Baranes et
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al, 1998; Pawlak et al, 2003; Norris and Strickland, 2007), and there is
evidence that strongly suggests tPA regulates these functions via direct
modulation of the NMDA-R (Norris and Strickland, 2007). In addition to
normal CNS physiology, inappropriate tPA activity also plays a role in CNS
pathology. tPA mediates excitotoxic neuronal death in the hippocampus
after kainic acid (KA) treatment, and tPA-deficient mice are protected from
KA-induced neurodegeneration (Tsirka et al, 1995; Chen et al, 1997; Indyk
et al, 2003). Furthermore, chronic ethanol increases tPA activity in the
hippocampus of adult mice. tPA interacts with the NR2B subunit of the
NMDA-R, and ethanol-induced increase of tPA is required for increase in
NR2B in the hippocampus, consequently resulting in ethanol withdrawal
seizures (EW) in adult animals and neurodegeneration (Pawlak et al, 2005;
Skrzypiec et al, 2008-submitted). Since tPA mediates ethanol-induced
modulation of the NMDA-R, which is a main target for ethanol in the CNS,
it became clear tPA was an appropriate candidate to investigate in the
development of FAS.

5

1.3 NMDA-R
Excitatory glutamatergic signaling mediated by the NMDA-R, a subtype
of glutamate ionotropic receptor, is critical during developmental
synaptogenesis. The heightened level of NMDA receptor activity during
development allows for increased influx of calcium, which acts as a
secondary signal, eventually leading to the translation of proteins required
for neuronal differentiation through activation of immediate early genes
(IEG) (Ghiani et al, 2007).
The NMDA-R complex consists of obligatory NR1 subunits that bind the
co-agonist glycine, assembled with NR2 subunits (NR2A, NR2B, NR2C)
that bind glutamate. A functional NMDA-R consists of two NR1, and at
least one type of NR2 (NR2A-D) (Cull-Candy et al, 2001). The composition
of NR2 is usually homomeric (i.e. NR2A/NR2A or NR2B/NR2B) and very
rarely heteromeric (e.g. NR2A/NR2B).

Each subunit consists of 4

transmembrane domains and an intracellular carboxyl terminal-domain
(CTD) and an extracellular amino-terminal domain (ATD).
The NMDA-R is a central target in the CNS for the neurobehavioral
effects of ethanol (Hoffman et al, 1989; Lovinger et al, 1989). Ion flux
through the NMDA-R is inhibited by ethanol, with the NR2A- and NR2Bcontaining receptors showing higher sensitivity to ethanol inhibition than
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NR2C- and NR2D-containing receptors (Masood et al, 1994; Mirshani and
Woodward, 1995). Furthermore, chronic ethanol exposure of adult animals
results in increased NMDA-R number, as determined by ligand binding
studies, and increased expression of NR1, NR2B, and NR2A (Grant et al,
1990; Follesa and Ticku, 1995; Snell et al, 1996).
The NR2 subunit composition confers different biophysical and
pharmacological properties on the receptor.

NR2B-containing receptors

have greater and longer acting excitatory post-synaptic currents (EPSCs)
than NR2A-containing NMDA-R (Cull-Candy et al, 2001; Sheng and Kim,
2002). In the mature brain, NR2B-containing receptors are mostly found at
extrasynaptic sites requiring higher concentrations of glutamate (spill-over)
than synaptic receptors to be stimulated, which has been speculated to
underlie the developmental changes observed in excitotoxicity (Zhou and
Baudry, 2006). Indeed, the expression and localization of the NR2 subunits
within the synapse are developmentally regulated (Sheng et al, 1994). The
NR2B subunit is predominant during synaptogenesis, while NR2A
expression does not rise until later postnatal stages near the end of the
synaptogenesis period in rodents. The localization of the subunits is also
developmentally regulated since increased NR2A replaces NR2B-containing
receptors as the main NMDA-R in the synapse, and NR2B becomes
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localized to extra-synaptic sites with its robust expression decreasing slightly
after the end of synaptogenesis (Liu et al, 2004).
Whether the NMDA-R contains NR2A or NR2B subunits can influence
neuronal survival or death. NR2B-specific blockade has been shown to
preclude apoptosis and necrosis after NMDA treatment, suggesting NR2B is
involved in promoting neuronal death. Conversely, antagonism of NR2Acontaining NMDA-Rs enhances apoptosis after NMDA, suggesting NR2A is
involved in neuronal survival (Liu et al, 2007). The differences in neuronal
survival due to subunit composition could stem from the coupling of
different signaling pathways downstream of the receptor complex and/or
differences in subcellular localization. In addition, the roles for NR2B and
NR2A might possibly vary depending on the developmental stage and brain
region (Lee et al, 2002, Hardingham et al, 2002). The role of NR3 subunits
is unclear, although reports suggest they have an inhibitory role on the
receptor and might be important for NMDA-R signaling at early
developmental stages (Perez-Otano and Ehlers, 2005; Yang et al, 2006;
Corlew, 2007).
The NMDA-R can be regulated in several ways that affect the function
and cell surface expression of the complex. The receptor can be internalized
via clathrin-dependent endocytosis (Lavezzari et al, 2004). This route of
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internalization is mediated by the phosphorylation state of tyrosine 1472 of
the NR2B subunit by Src kinases (Yu et al, 1997; Prybylowski, et al, 2005;
Zhang et al, 2008).

NR2B contains a binding sequence to the adaptor

protein complex 2 (AP-2), which is involved in the formation of clathrincoated pits, and when NR2B is phosphorylated at Y1472, AP-2 cannot bind
the subunit, and consequently the receptor is not internalized. The retention
of NR2B at the membrane also depends on the interactions of its CTD with
scaffolding proteins of the post-synaptic density such as post-synaptic
density protein 95 (PSD-95), which couples the NMDA-R to intracellular
signaling molecules that cluster and promote stabilization of the receptor
(Brenman et al, 1996; Sheng, 2001). Finally, the motility of the receptor at
the cell surface can also be determined by NR2 subunit composition, with
NR2A-containing receptors being more stable at the synapse than NR2Bcontaining ones (Groc et al, 2006). It is possible the stability of NR2A is
due to reduced interaction with PSD scaffolding proteins, since perturbations
of the NR2A CTD interactions with PSD scaffold proteins does not affect its
retention at the synapse (Groc et al, 2006).

9

1.4 NMDA-R-dependent signaling in FAS: nNOS and neurotrophic
factors
nNOS
Neuronal nitric oxide synthase (nNOS), the enzyme that produces nitric
oxide (NO) in the brain, is closely localized to the NMDA-R in the postsynaptic density. nNOS produces NO in response to NMDA-R-mediated
increases in Ca2+ influx (Bredt and Snyder, 1989; Garthwaite et al., 1989;
Kornau et al., 1997; Christopherson et al., 1999). nNOS has been implicated
as a source of protection from ethanol-induced neurotoxicity during brain
development.

Mice that are deficient in nNOS are more vulnerable to

neurodegeneration after exposure to ethanol in a mouse model of FAS
(Bonthius et al, 2006), indicating nNOS protects neurons from ethanolinduced toxicity (Bonthius et al, 2002). In vitro studies suggest nNOSmediated neuroprotection of developing neurons after ethanol is part of a
neurotrophic survival pathway stimulated by nerve growth factor (NGF) that
also requires CREB activation (Bonthius et al, 2003; Karacay et al, 2007).
nNOS possesses other neuroprotective effects in the CNS. These include
post-translational S-nitrosylation of the NMDA-R (Lipton and Stamler,
1994), caspases (Kim et al, 2002; Fiorucci, 2001) and p21ras (Yun et al,
1998; Chiueh, 1999; Ahern et al, 2002). NO can also lead to increased
expression of cytoprotective genes such as HSP70 (Sharp et al, 1999) and
10

Bcl-2 (Shimazaki et al, 1994; Kang et al, 2004). Furthermore ischemic
preconditioning-mediated neuroprotection is mediated by the NO and cyclic
guanosine monophosphate (cGMP) pathway and new protein expression
(Andoh, 2000; Atochin et al, 2003). Under pathological circumstances,
however, overproduction of NO and increased levels of reactive oxygen
species that can lead to the formation of peroxynitrite, a reactive agent
implicated in mechanisms of excitotoxicity after stroke (Keynes and
Garthwaite, 2004). S-nitrosylation and nitration of proteins by peroxynitrite
also exacerbate neurological disorders such as dementia (Giasson et al.,
2000), Parkinson's disease (Chung et al., 2004), and Alzheimer's disease
(Uehara et al., 2006).
The principal mechanism for NO action in the brain is through activation
of cGMP, which is stimulated by calcium via calmodulin and PKG
activation resulting in the modulation of ion channel function (Garthwaite et
al, 1988). Interestingly, the cGMP pathway also activates the anti-apoptotic
serine/threonine

kinase

Akt

by

PKG-dependent

activation

of

phosphatidylinositol 3-kinase (PI3 kinase) (Waxman and Lynch, 2005). Snitrosylation has recently emerged as a form of post-translational
modification of ion channels, thus providing a route for NO to regulate
electrical activity without stimulating production of cGMP. In the brain,
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PKG and S-nitrosylation enhance the activity of large conductance Ca2+activated K+ (BK) channels.

Neurotrophic factors: BDNF and NGF
As discussed previously, a great portion of the neuronal population is
eliminated through programmed cell death in early postnatal stages during
developmental synaptogenesis. Neurons enter apoptosis depending on their
proliferative or metabolic state, or the presence of extracellular signals, and
the subset that survives, do so through their ability to effectively connect to
appropriate targets that deliver neurotrophic factors essential for survival
(Hidalgo, 2003; Benn et al, 2004; Buss et al, 2006), forming synapses as a
result, and eventually, neural circuits.
The formation of new synapses relies on electrical activity between
afferent and target neurons (Katz and Shatz, 1996; Komuro and Rakic, 1998;
Penn et al., 1998; Spitzer et al., 2000; Stellwagen and Shatz, 2002), which
allow delivery of neurotrophic support and maturation of the synapse. This
model of activity-dependent survival comes from in vivo and in vitro studies
where cortical neurons have shown dependence on the activation of the
NMDA-R and the consequent synthesis/release of BDNF for survival
(Lessman et al, 2003; Suzuki et al, 2007). In the human brain this process
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starts in gestation and lasts for a few years after birth.

In rodents,

synaptogenesis is solely postnatal, occurring during the first 2 weeks after
birth.
Nerve growth factor (NGF) and brain-derived neurotrophic factor
(BDNF) are indispensable during developmental, and adult synaptogenesis
(Garofalo et al, 1992; Aguado et al, 2003). Ethanol exposure can decrease
the expression of BDNF and NGF, and the results vary depending on the
manner of administration, length of exposure, brain region, and
developmental period.

In vitro data support a neuroprotective role for

BDNF and NGF after ethanol exposure (Heaton et al, 1994; Climent et al,
2002).
tPA can aid in the maturation of pro-BDNF and pro-NGF through the
activation of the extracellular protease plasmin (Pang et al, 2004; Bruno and
Cuello, 2006). This process is essential for the formation of LTP in the adult
hippocampus (Pang et al, 2004). The survival-related properties of these
neurotrophic factors are mediated by the neurotrophic tyrosine kinase
receptors (Trk): BDNF binds TrkB and NGF binds and activates TrkA.
However, activation of the low affinity nerve growth factor receptor (also
known as the p75 neurotrophin receptor) by BDNF or NGF has been
associated with apoptotic neuronal death (Huang and Reichardt, 2001).
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1.5 Plasminogen activator inhibitor type 1 (PAI-1) in CNS physiology
As discussed earlier, inappropriate, elevated levels of tPA activity can
have detrimental effects in the brain. Plasminogen activator inhibitor type 1
(PAI-1), a member of the serine protease inhibitor (serpin) gene family, is
the primary inhibitor of tPA and urokinase (uPA) activity in the brain, and a
key regulator of fibrinolysis in the vasculature. PAI-1 irreversibly inhibits
tPA activity and abrogates the production plasmin (Lawrence et al, 1990).
Eventually, the tPA:PAI-1 complex can be cleared from the extracellular
space through LRP (Cao et al, 2006).
Most of PAI-1 is produced by astrocytes (Buisson et al, 1998; Hino et al,
2001), and previous work implicated astrocyte-derived PAI-1 in neuronal
anti-apoptotic signaling (Kimura et al, 2000; Soeda et al 2001). These
studies established that PAI-1 deficiency, in pheochromocytoma (PC12)
cells differentiated with NGF, resulted in a significant reduction of Bcl-2
and Bcl-XL mRNAs, which typically promote cellular survival, and an
increase in Bcl-XS and Bax mRNAs, which typically promote apoptosis
(Soeda et al., 2001).

As a result, pro-apoptotic signaling was favored

leading to cellular death.
Although basal PAI-1 levels are relatively low in the brain, they can
rapidly increase upon stimulation. An example of this is seen after intra-
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hippocampal delivery of the glutamate analog KA. The treatment increases
tPA activity and induces excitotoxicity in WT mice, whereas tPA-/- mice are
protected from neuronal injury (Tsirka et al, 1995).

PAI-1 mRNA is

upregulated following KA-induced increase in tPA activity (Masos and
Miskin, 1997), suggesting an elevation in tPA can trigger a subsequent
increase in PAI-1 leading to a decrease of the protease activity.
Furthermore, when exogenous PAI-1 was administered during KA injection,
neurodegeneration was abrogated (Tsirka et al, 1996), suggesting PAI-1
promotes neuronal survival via inhibition of tPA. However, since WT mice
not infused with PAI-1 do undergo neurodegeneration after KA, it is unclear
whether the reported increase in PAI-1 mRNA in WT reflects an increase in
protein levels that is sufficient to abolish tPA activity in a timely manner.
PAI-1 has also been implicated in cellular migration and neuritogenesis
during development. Recent research showed stimulation of muscarinic
receptors in astrocytes triggered the release of PAI-1, laminin, and
fibronectin, facilitating the extension of neurites during development
(Guizzeti et al, 2008). In addition, PAI-1 upregulation was required for
laminin- and fibronectin-mediated neuritogenesis.

It remained unclear

whether the involvement of PAI-1 was dependent or independent of tPA. It
is possible the presence of PAI-1 in the extracellular space precludes tPA-
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mediated degradation of laminin and possibly other components of the
matrix. In light of tPA’s involvement in ethanol-induced neurodegeneration
in the developing brain, we became interested in determining if PAI-1 is also
associated to ethanol-induced neurotoxicity. Since neuronal death plays a
pivotal role in the development and outcome of FAS, the identification of
the molecules that influence neurons’ vulnerability to ethanol’s effects is of
critical importance.

1.6 Chronic stress effects on hippocampal-dependent learning
Exposure to short-lasting stressful situations can induce plasticity
changes in the hippocampus that are necessary for learning, and ultimately
survival. However, the prolonged exposure to stressful stimuli can result in
maladaptive pathological effects on the hippocampus that might lead to the
development of anxiety disorders, posttraumatic stress disorders, and
depression (Miller and McEwen, 2006). Male rodents that are chronically
stressed by immobilization (6 hours/day for 21 days) have retracted dendritic
spines of hippocampal CA3 neurons, decreased body weight, and
impairments in spatial memory tasks (Tsien et al, 1996; McEwen BS, 1999;
Pawlak et al, 2005; McLaughlin et al, 2007).
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Chronic stress in the rat also suppresses dentate gyrus neurogenesis and
causes dendrites of hippocampal and medial prefrontal cortical neurons to
shrink (Gould, et al, 1998; Bennur et al, 2007; Cameron and Gould, 1994;
Cerqueira et al, 2005; Cook and Wellman, 2004). Interestingly, the same
treatment increases dendritic complexity and sprouting of new synapses in
neurons of the basolateral amygdala (Duvarci and Pare, 2007). Repeated
stress also increases fear and aggression and reduces spatial memory (Wood
et al, 2003; Conrad et al, 1996).
tPA is highly expressed in the adult hippocampus, and heavily involved
in synaptic plasticity events that underlie learning and memory.

Basal

extracellular tPA activity can be observed in the mouse hippocampus within
the mossy fiber pathway, with little or no activity or expression within the
perforant path, the Schaffer collaterals, or neuronal cell bodies (Salles and
Strickland, 2002). Hippocampal tPA has been implicated in LTP (Frey et
al., 1996; Huang et al., 1996; Baranes et al., 1998; Madani et al., 1999; Pang
et al, 2004), long-term depression (Calabresi et al., 2000), NMDA-Rmediated signaling (Nicole et al., 2001; Norris and Strickland, 2007), and
synaptic remodeling (Baranes et al., 1998; Neuhoff et al., 1999).
Additionally, overexpression of tPA enhances long-term potentiation (LTP)
and improves performance in the Morris water maze (Madani et al., 1999).
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tPA is a key mediator of the structural and molecular changes that ensue
in the hippocampus as a result of repeated exposure to stressful stimuli.
Mice deficient in tPA and plasminogen are protected from stress-induced
decrease in NMDA-Rs and reduction in dendritic spines, and show impaired
acquisition, but not retrieval, of hippocampal-dependent spatial learning in
the Morris water maze (Pawlak et al, 2005). Since tPA is a key target of the
stress response in the hippocampus, we sought to determine if chronic stress
regulates the tPA/PAI-1 system in this brain region. We observed chronic
stress modulated the tPA system in the hippocampus, and the changes
observed were associated to impairments in learning and memory.
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CHAPTER 2: MATERIALS AND METHODS
2.1 Animals
C57/BL6/J WT, tPA-/-, PAI-1-/-, and Plg-/- mice backcrossed for at least 10
generations were used in all the experiments. Mice were maintained in the
Comparative Bioscience Center (CBC) with a controlled humidity,
temperature, and light/dark cycle (7:00 am to 7:00 pm light). All animal
procedures were according to protocols approved by the Institutional Animal
Care and Use Committee (IACUC).

2.2 Polymerase Chain Reaction (PCR)
DNA from tail tissue was obtained at the moment of sacrifice. Tails were
digested overnight at 55 degrees in a mix of lysis buffer & Proteinase K.
DNA was extracted and PCR product samples run on 2% agarose gel. The
tPA primers were: T881 TTGTGTCGTGCCAGGCCGAGTGCC, T731
GCTATGTTGGGAAAGGTGTGACTTACCG,PGKnSATTAAGGGCCAG
CTCATTCCTCCC. PAI-1primers: 2726
GAGTGGCCTGCTAGGAAATTCATTC,2312GACCTTGCCAAGGTGA
TGCTTGGCAAC,PGKpAAATGTGTCAGTTTCATAGCC.
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2.3 Materials
Human recombinant tPA was provided by Genentech (South San Francisco,
CA) and dissolved in phosphate buffered saline (PBS). Plasminogen for gel
zymographies was isolated from human plasma provided by the New York
Blood Center (Deutsch and Mertz, Science, 1970). The tPA inhibitor, tPASTOP, was purchased from American Diagnostica (Stamford, CT) and the
mutant S481A inactive tPA was obtained from Molecular Innovations
(Novi, MI). MK801 was purchased from Calbiochem (San Diego, CA),
Ro25-6981 was purchased from Tocris (Ellisville, MO). Diazepam was
purchased from Sigma (St. Louis, MO).

2.4 Acute ethanol treatment
Although synaptogenesis begins during pre-natal stages in humans, this
process occurs post-natally in mice during the first two weeks after birth.
Therefore pups were used at post-natal day 7 (P7) in these studies. Pups
were injected subcutaneously (s.c.) with two injections of 2.5g/kg ethanol
(prepared as a 20% solution in sterile saline) at 0 hour and 2 hours. Control
pups were injected with an equal volume of sterile saline.
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2.5 tPA in-gel zymography
Forebrains from saline and ethanol-treated WT mice were removed and
homogenized in 100 mM Tris containing 0.2% Triton X-100 and
phosphatase inhibitors.

After protein determination by the BCA Assay

(Pierce, Rockford, IL), the homogenates were prepared to equal
concentrations in non-reducing loading buffer and kept on ice. Samples
were loaded on 10% separating gels containing casein and plasminogen.
Upon completion, gels were rinsed in 2.5% Triton X-100 twice for 45 min at
37oC and then incubated overnight at 37oC in 0.25% Triton X-100. The
following day, gels were stained with Coomassie Blue R-250 for 30 minutes
and then destained with 10% acetic acid to visualize tPA activity. The bands
representing tPA activity were quantified with Scion software (NIH).

2.6 in situ zymography
To determine hippocampal extracellular tPA activity after 21 days of chronic
restraint stress, 20 µm thick sections were incubated with an overlay mixture
containing casein and plasminogen. The sections were then coverslipped
and incubated at 37° C until dark zones of lysis became visible in the
hippocampus. The sections were then observed in the microscope using a
dark field setting, and pictures were taken and stored for analysis at a later
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time. tPA activity (lytic zones) was analyzed using Image J (NIH). Briefly,
the area of lysis was determined, and divided by the total hippocampal area,
and multiplied by 100 to determine the percentage area of lysis.

2.7 Fluorescent in situ zymography
To determine extracellular tPA activity in neonatal mice after ethanol (or
saline) exposure, 20 µm thick sections were incubated with an overlay
mixture containing plasminogen and fluorescently quenched casein
(Molecular Probes, Oregon), that fluoresces when cleaved by plasmin. The
sections were then coverslipped and incubated at 37° C for 2. The sections
were then observed in a fluorescent microscope (Zeiss Axioscope) using the
fluorescein filter to visualize the areas of lysis, and pictures were taken and
stored for analysis at a later time.

2.8 Immunoprecipitation and western blotting
Immunoprecipitation

Samples of forebrain homogenates from ethanol- or saline-treated mice were
adjusted to equal protein concentration and precleared with preimmune IgG
and Gamma Bind Plus Sepharose beads (Amersham Biosciences,
Piscataway, NJ). The monoclonal anti-NR2B antibody (NeuroMab facility,
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UC Davis, CA) was added for 1 hr, followed by incubation with Sepharose
beads overnight at 4°C. Beads were washed with PBS and heated to 100°C
for

5

min

in

loading

buffer

containing

DTT.

Following

immunoprecipitation, we probed for ß-adaptin and NR2B by western blot.

Western blotting

Forebrain homogenates of saline and ethanol-treated WT and tPA-/- mice
were prepared as described above. All samples were prepared to equal
amounts of protein concentration, as previously determined by BCA assay.
After protein separation on 4-15% pre-cast gradient Tris-Glycine
polyacrylamide gels and transfer onto nitrocellulose membranes, blots were
blocked in 5% milk and incubated in primary antibody overnight at 4oC.
Blots were rinsed in Tris buffered saline containing 0.1% Tween-20 (TBST), and then incubated in secondary antibody for 1 hr at room temperature
followed by rinsing in TBS-T before exposure to film. Bands were scanned
and quantified with the Scion software (NIH), and normalized to betatubulin.
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2.9 Antibodies
Polyclonal anti-caspase-3 (1:500) antibody was obtained from Cell
Signaling; monoclonal anti-cytochrome c (1:500) from BD Pharmingen;
polyclonal anti-NGF (1:500), anti-BDNF (1:500), anti-NR1 (1:1000) and
anti-cFOS (1:500), and ß-adaptin (1:500) were purchased from Santa Cruz
Biotechnology; polyclonal anti-tPA from Molecular Innovations and
American Diagnostica: polyclonal anti-phospho GAP-43 (1:1000) and antiGAP-43 (1:1000) from Chemicon; polyclonal anti-nNOS (1:1000) from
Biomol; anti-cleaved caspase-3 from Cell Signaling; anti-NR1 from Santa
Cruz Biotechnology; monoclonal anti-PSD-95 from Sigma; polyclonal antiNR2B from PhoshoSolutions; monoclonal anti-NR2B from the NeuroMab
facility; polyclonal anti-phospho NR2B (Y1472) from Imgenex; and antiNR2A from Upstate Biotechnologies.

2.10 Cleaved Caspase-3 Immunostaining
Saline- and ethanol-treated WT and tPA-/- mice were deeply anesthetized
and transcardially perfused with normal saline and 4% paraformaldehyde.
Brains were removed and post-fixed in 4% paraformaldehyde for 48 hrs,
followed by immersion in 30% sucrose until sinking. Brains were then
frozen, sectioned at 20 um, and mounted on slides. The slides were allowed

24

to air-dry overnight. The following morning they were incubated in blocking
buffer (1% BSA, 5% goat serum, 0.5% Triton X-100, in PBS) for 2 hours at
room temperature, followed by primary antibody (anti-cleaved caspase-3
alexa fluor 488-conjugated, Cell Signaling, 1:500) incubation in blocking
buffer at 4°C overnight. The following morning sections were washed in
PBS with Triton X-100, coverslipped, and observed in the fluorescent
microscope.

2.11 tPA Immunostaining
tPA-/- P7 mice that had been treated with S481A tPA and ethanol (or saline),
were deeply anesthetized and transcardially perfused with normal saline and
4% paraformaldehyde.

Brains were removed and post-fixed in 4%

paraformaldehyde for 48 hrs, followed by immersion in 30% sucrose until
sinking. Brains were then frozen, sectioned at 20 um, and mounted on
slides. The slides were allowed to air-dry overnight. The following morning
they were incubated in blocking buffer (1% BSA, 5% goat serum, 0.5%
Triton X-100, in PBS) for 4 hours at room temperature followed by primary
antibody incubation (anti-tPA, Molecular Innovations 1:500; anti-tPA,
American Diagnostica 1:500) or preabsorbed primary antibody incubation in
blocking buffer at 4°C overnight. Preabsorbtion was done by incubation of
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the primary antibodies with tPA-/- tissue for 4 hrs at room temperature
(Salles and Strickland, 2002). Slides were then washed with Triton X-100,
and incubated with fluorescently tagged secondary antibody. After
incubation, the sections were washed coverslipped, and observed in the
fluorescent microscope.

2.12 PAI-1 Enzyme-Linked Immuno Sorbent Assay (ELISA)
Forebrain homogenates from saline- and ethanol-treated WT mice were
prepared as described above. Samples were prepared in duplicates (200 ug
of protein each) and the ELISA was performed using a kit (Molecular
Innovations, Novi, MI) according to the manufacturer’s instructions.

2.13 Fluoro-Jade B staining
Mice were deeply anesthetized and transcardially perfused with normal
saline and 4% paraformaldehyde. Brains were removed and post-fixed in
4% paraformaldehyde for 48 hrs, followed by immersion in 30% sucrose
until sinking. Brains were then frozen and sectioned at 40 um on a cryostat.
Sections were collected in PBS, mounted on slides, and allowed to air dry
for 24 hrs. After drying, the slides were stained with Fluoro-Jade B (FJB) as
has been previously described (Schmued and Hopkins 2000; Toscano et al.
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2008). FJB detects neuronal damage by staining neurons undergoing
necrosis or apoptosis a fluorescent green color.

2.14 Fluoro-Jade B quantitation and analysis
Quantitation was done as described previously (Paul et al, 2007). Upon
completion of FJB staining the slides were observed on the fluorescent
microscope with the appropriate filter. All pictures from animals from the
same experiment were taken the same day with the same exposure settings.
A minimum of 3 slices per animal and brain region was used for
quantification purposes. Images taken with the 20X objective were obtained
using a camera attached to the microscope and stored for later analysis.
Image J (NIH software) was used to quantify FJB-positive staining. Images
of the area of interest (e.g cingulate cortex, hippocampus, thalamus) were
converted to 1-bit, the background substracted from the image, and the
positive-labeled cells counted by the program.
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2.15 Blood Ethanol level determination
Plasma EtOH levels were analyzed with the EnzyChrome kit by BioAssay
Systems according to the manufacturer’s directions.

2.16 Evans Blue extravasation
Neonatal P7 and adult P90 WT and tPA-/- mice were injected transcardially
with a solution of 2% Evans blue/PBS (4 ml/kg) dye, or control buffer.
Fifteen minutes after Evans blue injection, animals were perfused with PBS,
and their brains collected for analysis. The brains were sectioned in a
freezing cryostat and observed in the fluorescent microscope, the presence of
Evans Blue was observed in the brain parenchyma of young, but not the
adult animals.

2.17 Restraint stress
Adult (10-12 weeks of age) WT, tPA-/-, and PAI-1-/- mice were immobilized
in wire mesh restrainers and placed in their homecage. Chronic stress lasted
6 hours a day, for 21 consecutive days. The restrainers were secured with
clips to avoid having the mice escape from them. On an occasion, a mouse
bit through the restrainer and escaped immobilization, this mouse was
sacrificed and eliminated from the study.
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Control animals were not

restrained, and were kept in a different room than stress mice. We fed,
changed water bottles, and cleaned their cages in order to minimize
unnecessary stress by the CBC staff.

2.18 Fear Conditioning
Fear conditioning was done on adult mice (8-10 weeks of age) that had been
exposed to ethanol or saline at P7. In a separate study, chronically stressed
(or non-stressed control) mice, were also tested in this paradigm.

The

conditioning chambers were equipped with a speaker, house light, and a
video camera. The chamber floors consisted of rods that were connected to a
shock generator. Mice were habituated to the behavioral room for 1 hour on
the day of training and placed individually into a conditioning chamber
cleaned with an ammonia-based solution for 2 minutes, this time was
considered the “baseline period”. Mice were then exposed to three tonefootshock pairings (tone, 20 sec, 85 dB, 3.5 kHz; footshock, 1 sec, 0.6 mA)
with an inter-trial interval of 60 sec. Upon completion of training, mice
were returned to their home cages and room and tested 24 hrs later. The
training sessions were video recorded in order to analyze the animals’
baseline freezing behavior (every 5 sec) during training. On testing day,
mice were habituated to the behavioral room for 1 hr. Mice were then
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placed individually into the same chamber (same scent, lighting, etc.) as the
previous day for a 2-minute period, during which time their behavior was
recorded. Freezing behavior, or the complete lack of movement, in response
to the context, was scored every 5 sec.

2.19 Statistical analyses
Data are presented as mean ± SEM. Between-group comparisons were
performed with factorial ANOVA and Tukey post-test. P values <0.05 were
considered significant. Numbers of animals in each experiment and the
statistical significance are presented in figure legends.

30

CHAPTER 3: RESULTS
3.1 Ethanol treatment increased neuronal-associated tPA activity in
perinatal mouse pups
tPA and PAI-1 activities were determined following the administration of
sedating doses of ethanol (2.5 g/kg at 0hr and 2 hr) to wild-type (WT) mouse
pups postnatal day 7 (P7). Gel zymography of forebrain homogenates showed
tPA activity slightly, but not significantly, increased 30 minutes after ethanol
intake (Figure 1A and 1C).

Three hours post-ethanol administration tPA

activity was significantly elevated over 1.5 fold above control levels. tPA
activity peaked with a 2-fold increase at 6 hours, and continued to be
significantly increased at 24 hrs (Figure 1B and 1C) following ethanol
administration. Increased tPA activity, represented as green fluorescence, was
visibly localized to the cortex, hippocampus, and thalamus of WT mice treated
with ethanol using in situ zymography, which detects extracellular activity of
the protease, 3 hours post-ethanol. (Figure 1D, 1E, and 1F respectively).
Localized increase of tPA activity could be the result of upregulation of
tPA expression or a decrease in PAI-1 expression.

Therefore, tissue

homogenates from WT P7 mice treated with ethanol were also examined for the
expression of free and complexed (i.e. total) PAI-1 using an enzyme-linked
immunosorbent assay (ELISA). PAI-1 antigen was increased approximately 3-
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fold above baseline levels in the WT brain 30 minutes after ethanol treatment,
but was reduced to baseline at 3 hours, and downregulated below the baseline
by 24 hours following the administration of ethanol (Figure 1G). The pattern of
neurotoxic insult after ethanol leading to elevated tPA activity and increased
PAI-1 is not consistent with the pattern previously observed by Masos and
Miskin in adult mice following kainic acid (KA) treatment (Masos and Miskin,
1997). In the KA scenario, the hippocampal increase in tPA was followed by a
subsequent increase in PAI-1. Here we observe an opposite pattern where
ethanol increased PAI-1 levels prior to the increase of tPA activity. Also,
ethanol induced downregulation of PAI-1 below the baseline 24 hours after
treatment when tPA levels remain significantly elevated.
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Figure 1. Ethanol treatment increased neuronal-associated tPA activity
in perinatal mouse pups. WT mice (P7) were injected subcutaneously (s.c)
with ethanol (referred to as EtOH in the figures) in 2 doses of 2.5g/kg at
times 0 hr and 2hr (N=5-6). Control mice were injected with equal volumes
of saline. Mice were sacrificed at different time-points, the forebrain was
homogenized, and tPA activity assayed by in-gel zymography (A and B) and
in situ zymography (D, E, F). Quantification of gel zymographs (C) showed
tPA activity was significantly increased in the forebrain of WT mice 3 hr
after EtOH (*, P < 0.05). tPA activity remained increased at later timepoints up to 24 hrs (**, P < 0.001). In situ zymography showed extracellular
tPA activity is localized to the cortex (D), thalamus (E), and hippocampus
(F) of WT mice 3 hrs after ethanol, as observed by green fluorescence (blue
is DAPI staining). PAI-1 was assayed with an ELISA. PAI-1 levels were
increased significantly (***, P< 0.0001) 0.5 hr after treatment, returned to
baseline at 3 hr post-ethanol, and were downregulated (*, P < 0.05) 24 hrs
post-ethanol.
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Figure 1
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3.2

tPA

upregulation

corresponds

to

increased

apoptotic

neurodegeneration after ethanol
Increased tPA activity promotes excitotoxin-induced neurodegeneration
as seen following kainic acid treatment and ethanol withdrawal seizures in the
hippocampus of adult mice. To determine whether the increased tPA activity
seen in P7 mouse brain following ethanol treatment was similarly associated
with neuronal loss, we used Fluoro-Jade B staining to identify areas of
neurodegeration in WT and tPA-/- mice 24 hours after ethanol treatment.
Neuronal loss was widespread throughout the WT forebrain (Figure 2 and
Figure 3). The most vulnerable areas included the cingulate cortex which
exhibited ~120-fold increase in neuronal loss above saline-treated controls
(Figure 2A and 2D), and the thalamus with ~150-fold increase in
neurodegeneration above control (Figure 3A and 3D). In a stark contrast, tPA-/mice showed significant attenuation in neuronal loss in both the cortex (Figure
2C and 2F) and thalamus (Figure 3C and 3F) after ethanol treatment.
The effect of tPA on neurodegeneration as detected by Fluoro-Jade B
staining was gene dosage-dependent, as tPA mice heterozygous for tPA
deficiency showed an intermediate phenotype in both the cortex (Figure 2B and
2F) and thalamus (Figure 3B and 3F) when compared to WT and tPA-/- animals.
Ethanol induced a ~3.6-fold increase in neurodegeneration in the WT
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hippocampus (Figure 4A and 4E) compared to a ~0.8-fold increase seen in the
tPA-/- (Figure 4B and 4E). The absence of significant neuronal death in the
hippocampus observed in this study is consistent with previous studies of FAS
in neonatal mice (Ikonomidou et al, 2000) in which the same protocol did not
affect the hippocampus to the same magnitude it did the cortex and thalamus.
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Figure 2. Ethanol induces neurodegeneration in the cortex of WT mice,
but not tPA-/-. WT, tPA-/-, and tPA+/- P7 mice were injected with ethanol or
saline as control (N = 6-7/group). 24 hrs after treatment, animals were
sacrificed and brain sections analyzed histologically with Fluoro-Jade (FJB)
to visualize neurodegeneration. Ethanol induced extensive neuronal death in
the cortex of WT (A) when compared to saline-treated mice (D) (***, P <
0.0001).

tPA-/- mice, however, are significantly protected from

neurodegeneration after ethanol (C) in comparison to the saline group (F) (*,
P < 0.05).

tPA+/- showed intermediate neurodegeneration (B) when

compared to the WT (A) and tPA-/- (C) brains after ethanol (**, P < 0.001).
There was no difference in basal (saline-treated) neurodegeneration between
any of the groups.
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Figure 3. Ethanol induces neurodegeneration in the thalamus of WT
mice, but not tPA-/-. WT, tPA-/-, and tPA+/- P7 mice were injected with
ethanol or saline as control (N = 6-7/group). 24 hrs after treatment, animals
were sacrificed and brain sections analyzed histologically with Fluoro-Jade
(FJB) to visualize neurodegeneration. Ethanol induced extensive neuronal
death in the thalamus of WT (A) when compared to saline-treated mice (D)
(***, P < 0.0001). tPA-/- mice, however, are significantly protected from
neurodegeneration after ethanol (C) in comparison to the saline group (F) (*,
P < 0.05).

tPA+/- showed intermediate neurodegeneration (B) when

compared to the WT (A) and tPA-/- (C) brains after ethanol (**, P < 0.001).
There was no difference in basal (saline-treated) neurodegeneration between
any of the groups.
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Figure 4. Ethanol induces neurodegeneration in the hippocampus of
WT mice, but not tPA-/-. WT and tPA-/- P7 mice were injected with ethanol
or saline as control (N = 6-7).

24 hrs after treatment, animals were

sacrificed and brain sections analyzed histologically with Fluoro-Jade (FJB)
to visualize neurodegeneration. Ethanol induced modest, but significant
neuronal death in the hippocampus of WT (A) when compared to salinetreated mice (C) (*; P > 0.05).

tPA-/- mice did not display significant

neurodegeneration in the hippocampus after ethanol (B) either (P > 0.05).
There was no difference in basal (saline-treated) neurodegeneration between
any of the groups.
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It was possible that the difference in neurodegeneration during
synaptogenesis in tPA-/- and wild type could have been an artifact of differing
blood ethanol concentrations, perhaps reflective of underlying metabolic
differences between the two genotypes, and not to a primary difference in
neuronal physiology. To address this possibility, we determined the blood
ethanol concentrations following treatment with the acute binge paradigm
described earlier (2.5g/kg ethanol at 0 and 2 hours). We found no difference in
blood ethanol concentrations between tPA-/- and WT mice (Figure 5) at any
timepoint studied. This result verifies that the observed neuroprotection in the
tPA-/- mice was not due to differences in the rate of ethanol metabolism between
mouse genotypes.

Figure 5. Blood ethanol concentrations are similar in WT and tPA-/pups. WT and tPA-/- P7 mice were injected with ethanol as previously
described. Mice were decapitated at different time-points after treatment,
trunk blood was collected, and plasma was assayed to determine ethanol
concentration. WT and tPA-/- mice show similar concentration of ethanol in
plasma at all the time-points evaluated. (P > 0.05)
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Ethanol-induced apoptotic neurodegeneration during synaptogenesis is
mediated by BAX, requires the release of cytochrome c from the mitochondrial
membrane, and culminates with the activation of caspase-3 (Olney et al, 2000
and 2002; Young et al, 2003 and 2005). To determine if activation of ethanolinduced apoptosis during synaptogenesis is tPA dependent, we examined tissue
homogenates and sections for cleaved caspase-3 and cytochrome c
immunoreactivity. WT mice showed an increase in activation of caspase-3 as
observed by western blot (Figure 6A and 6B) and immunohistochemistry
(Figure 6C), and cytochrome c immunoreactivity (Figure 6E) eight hours after
ethanol treatment as previously noted (Olney et al, 2000 and 2002; Young et al,
2003 and 2005). tPA-/- mice did not exhibit changes in active caspase-3 (Figure
6A, 6B, and 6D) or cytochrome c (Figure 6F) immunoreactivity concomitant
with the lack of neuronal loss observed in these mice.
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Figure 6. Ethanol induces caspase-3 activation and cytochrome c
immunoreactivity in WT, but not tPA-/- mice. WT and tPA-/- P7 mice were
injected with ethanol or saline and sacrificed 8 hrs post-treatment. Ethanol
induced the activation of caspase-3 in the forebrain of WT mice (**, P <
0.001) but this activation was not seen in the tPA-/- (A and B).
Immunohistochemistry showed ethanol dramatically increased caspase-3
and cytochrome-c reactivity (C and E) in WT mice, but not tPA-/- (D and F).
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In case tPA-/- mice were resistant to ethanol-induced neurodegeneration
as a result of underlying developmental abnormalities distinct from the acute
ethanol insult and not as a direct effect of tPA activity upregulation following
ethanol ingestion, we used the small molecular weight tPA-specific inhibitor
tPA-STOP to deplete tPA activity (Figure 7I and 7K) instead of making use of
genetically deficient tPA mice. WT mice were injected intra-peritoneally (i.p.)
with tPA-STOP (10ug/g) 30 minutes before the first ethanol treatment. FluoroJade B staining showed that the mice pre-treated with tPA-STOP exhibited
reduced neurodegeneration after ethanol when compared to the group treated
only with ethanol (Figure 7). The cingulate cortex showed ~80 fold reduction
in neurodegeneration when compared to the ethanol-treated group (Figure 7B
and 7G). The thalamus showed greater reduction in neuronal loss than the
cortex ~100 fold (Figure 7E and 7H). Forebrain samples collected from WT
mice treated with both tPA-STOP and ethanol did not have as extensive an
upregulation of tPA activity compared to WT mice that did not receive tPASTOP at 3 and 6 hrs post-Ethanol (Figure 7J and 7L). This result is consistent
with that seen using tPA-/- mice and suggests that the effect of tPA in ethanolinduced neurodegeneration is an acute effect of tPA upregulation.
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Figure 7. tPA-STOP attenuates ethanol-induced neurodegeneration in
WT mice. WT P7 mice were injected with tPA-STOP (10ug/g body weight)
30 mins prior to the first ethanol injection. tPA-STOP pre-treated mice
exhibited reduced neurodegeneration when compared to mice treated with
EtOH alone. tPA-STOP attenuated neurodegeneration by ~80 fold in the
cortex (A, B, and G; ***, P < 0.0001) and over 100 fold in the thalamus (D,
E, and H; ***, P < 0.0001). tPA-STOP administered along with saline did
not result in any changes in neurodegeneration (C and F). 1 ng of active tPA
was incubated with 14 ug of tPA-STOP (1ug/ul) for 3 hrs at room
temperature. tPA activity was reduced by ~60% (I and K). Mice pre-treated
with tPA-STOP were sacrificed 3 and 6 hrs post-EtOH, their forebrains
removed, and the homogenates assayed for tPA activity by in-gel
zymography (J). Mice pre-treated with tPA-STOP before EtOH showed an
attenuated increase in tPA activity compared to what was previously
observed when treated with EtOH alone (L; * P < 0.05, *** P < 0.0001).
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Figure 7
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3.3 tPA induction of neurodegeneration is plasminogen-independent
The mechanisms by which tPA has previously been shown to induce
neurodegeneration include 1) activation of plasminogen to plasmin with
subsequent proteolysis of the supporting extracellular matrix surrounding
neurons: 2) microglial activation: and 3) via direct modification of the NMDAR.

We observed increased CD11b immunoreactivity, characteristic of

microglia reactivity, in the cortical (Figure 8C) and thalamic (Figure 8G)
regions of WT, but not tPA-/- mice (Figure 8D and 8H) 24 hrs after ethanol
exposure. To determine whether tPA activation of plasminogen to plasmin was
necessary for tPA-induced neurodegeneration in our system, plasminogendeficient mice (Plg-/-) mouse pups were treated with ethanol at postnatal day-7,
and examined for neurodegeneration as previously done with tPA-/- and wild
type animals. There was no difference between the extent of neurodegeneration
in Plg-/- and wild type mice (Figure 9), suggesting that tPA acts independently
of plasmin in this system.
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Figure 8. WT mice, but not tPA-/-, show increased CD11b
immunoreactivity after ethanol.

WT and tPA-/- P7 mice treated with

ethanol or saline (N = 6-7) were sacrificed 24 hrs after treatment, and their
brains examined histologically for a marker of microglial activation. WT
mice showed enhanced immunoreactivity to an anti-CD11b FITCconjugated antibody 24 hrs after ethanol treatment in the cortex (C) and
thalamus (G). tPA-/- mice did not show increased immunoreactivity after
ethanol in either brain region (D and H). There were no baseline differences
in CD11b immunoreactivity in any group (A, B, E, F).
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Figure 9. tPA-mediated neurodegeneration after ethanol is plasminindependent. To investigate if tPA-mediated neuronal death after ethanol is
plasmin dependent, we injected WT and plasminogen-deficient (Plg-/-) P7
mice with ethanol or saline as control (N = 6/group). 24 hrs after treatment,
animals were sacrificed and brain sections analyzed histologically with
Fluoro-Jade (FJB) to visualize neurodegeneration.

Ethanol induced

extensive neuronal death in the cortex (A) and thalamus (B) of WT mice.
Plg-/- deficient mice showed ethanol-induced neurodegeneration in the cortex
(C) and thalamus (D) to a similar degree and pattern previously observed in
the WT mice. There was no difference in basal (saline-treated)
neurodegeneration between any of the groups.
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3.4 tPA induction of neurodegeneration is independent of its proteolytic
activity
To determine if restoration of tPA antigen to tPA-/- mice was sufficient to
restore neurodegeneration as observed in the WT mouse after ethanol exposure,
we treated P7 tPA-/- mice with exogenous tPA. Since P7 mice cannot undergo
stereotaxic surgery, and peripherally circulating active tPA can compromise the
integrity of the blood brain barrier (BBB) (Yepes et al, 2003), we opted for
peripheral administration of tPA which has a mutation from serine to alanine at
residue 481 (S481A). This mutation renders the proteinase catalytically inactive
(see Figure 10G) and (Olson et al, 2001). tPA-/- mice were injected with S481A
tPA (1µg/g) 30 minutes before the first ethanol treatment.

Fluoro-Jade B

analysis revealed a partial, but significant, restoration of the ethanol-induced
neurodegeneration in the tPA-/- mice that were pre-treated with S481A tPA
(Figure 10). The effect was surprisingly greater in the cortex with a ~80-fold
increase (Figure 10B and 10E) than in the thalamus where the increase was in
neuronal death was ~50-fold (Figure 10D and 10F). To verify that S481A
reached the brain parenchyma in our P7 mice, we examined S481A-treated P7
tPA-/- mouse brain sections by immunohistochemistry (IHC). The commercially
available antibodies against tPA were not specific when observed by western
blot (data not shown) and IHC, yielding high cross-reactivity with a milieu of
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other molecules (Figure 10L). When the antibody was incubated with a tPA-/forebrain slice at room temperature for 4 hrs the specificity of the antibody
greatly increased (Figure 10M). Our results show there was positive staining
for tPA in the brain of tPA-/- mice treated with S481A (Figure 10H and 10I) but
not in the tPA-/- brain of mice treated with saline (Figure 10M).
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Figure

10.

S481A

tPA

partially

restores

ethanol-induced

neurodegeneration in the tPA-/- mouse. tPA-/- P7 mice were injected with
S481A tPA (1ug/g) 30 mins prior to ethanol exposure. Mice were also
injected with saline as a control, or with ethanol alone. Mice pre-treated
with S481A tPA before ethanol showed a partial restoration of
neurodegeneration (B and D) when compared to mice treated with ethanol
alone (A and C). Significant FJB-positive staining was seen in the cortex (B
and E; ***, P < 0.0001) and thalamus (D and F; ***, P < 0.0001) of tPA-/mice pre-treated with S481A tPA prior to ethanol. S481A tPA lacked
enzymatic activity when compared to the same amount of active tPA by ingel zymography (G). S481A tPA could be observed in the brain of tPA-/mice with an anti-tPA that had been pre-adsorbed in tPA-/- tissue (H and I).
We did not observe immunoreactivity when the 1º antibody was not present
(J). When the anti-tPA antibody was not pre-adsorbed, immunostaining of
saline treated tPA-/- samples was non-specific (L).

Specificity greatly

increased when the antibody was pre-adsorbed as seen by the reduction in
background intensity (M).
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Figure 10
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This result is particularly interesting because the blood brain barrier
(BBB) does not permit the entrance of macromolecules into the brain and raises
the question of whether there might be an activity-independent transport
mechanism for tPA.

An alternative possibility was that the BBB is

incompletely developed in P7 mice facilitating passive transport of S481A tPA
(Risau et al, 1994; Xu et al, 1993; Butt et al, 1990). To determine which of
these possibilities was the case, BBB permeability was examined in P7 and P90
mice that were injected transcardially with Evans Blue, a dye with high affinity
for albumin, which does not cross the mature BBB under physiologic
conditions. Fifteen minutes after Evans Blue injection, mice were perfused
with PBS, their brains collected and sectioned in a freezing cryostat, and the
sections examined by fluorescent microscopy. Evans Blue dye was observed in
the brain parenchyma of the P7 WT and tPA-/- mice (Figure 11A and 11B), but
not of the adult P90 mice (Figure 11C and 11D). As expected, the mice
injected with saline were not positive for Evans Blue (Figure 11E and 11F).
These data suggest the BBB was incomplete at the younger age, and tPA
transport into the CNS parenchyma was not the result of a tPA-specific
transporter.
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Figure 11. The P7 mouse blood brain barrier is permeable to Evans
Blue extravasation. Since peripherally administered S481A tPA reached
the brain parenchyma, we sought to determine the permeability of the blood
brain barrier (BBB) in P7 mice using Evans Blue (EB). We observed the
presence of EB (red fluorescence) in the ventricle of tPA-/- mice (A and B),
around the hippocampal formation (C), and around the cortex (D). There
was no EB fluorescence in the untreated P7 tPA-/- ventricle (E). Adult tPA-/treated with EB did not show its presence in the cortical area (F). (Blue is
DAPI staining)
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3.5 tPA promotes neurodegeneration by downregulating neurotrophic
factor expression following ethanol ingestion
Brain derived neurotrophic factor (BDNF) and nerve growth factor (NGF)
promote neuronal growth and survival through activation of the TrkB receptor,
and are of particular importance during early developmental stages of synapse
formation (for reviews see Luikart and Parada, 2006; Nagappan and Lu, 2005).
tPA can convert pro-BDNF and pro-NGF to their mature forms through the
activation of the extracellular protease plasmin (Pang et al, 2004; Bruno and
Cuello, 2006).

We observed ethanol treatment significantly increased the

protein levels of both NGF 1.5-fold and BDNF 1.5-fold in the tPA-deficient
pups 24 hours after treatment (Figure 12). The effect of was opposite in WT
mice, ethanol decreased NGF and had no effect on BDNF (Figure 12).
Interestingly, WT pups showed higher baseline protein levels of NGF than tPA/-

(Figure 12). These data suggest that prolonged and elevated levels of tPA

activity in the WT brain after ethanol might lead to inappropriate processing of
pro-BDNF and pro-NGF, perhaps leading to their degradation. However, since
tPA-mediated neurotrophic maturation requires plasmin, and Plg-/- mice show a
phenotype after ethanol that resembles WT, it is more likely the changes in
BDNF and NGF observed are due to proteolysis-independent effects of tPA.
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Figure 12. Ethanol increases forebrain neurotrophic factor expression
in the absence of tPA. WT and tPA-/- P7 mice were treated with ethanol or
saline and sacrificed 24 hrs later. The brains were removed and the
forebrains homogenized and analyzed by western blot for BDNF and NGF
levels (A). Baseline levels of BDNF were similar in both genotypes, while
NGF was initially higher in the WT than in the tPA-/- (A).

Ethanol

significantly increased both BDNF and NGF in the tPA-/-, but not the WT
(B). The effect was stronger for NGF (**, P < 0.001) than BDNF (*, P <
0.05) in the tPA-/- brain. BDNF remained the same after ethanol in the WT,
and NGF was downregulated below the baseline (*, P < 0.05).
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3.6 Ethanol does not suppress synaptic activity markers in the tPA-/- mice
One mechanism by which NGF may protect against neurodegeneration is via
induction of nitric oxide (Bonthius et al, 2003). Nitric oxide (NO) has recently
been shown to protect against ethanol-induced damage in the developing brain
(Bonthius et al, 2002 and 2006) via a cGMP/PKG pathway. NO is produced by
neuronal nitric oxide synthase (nNOS) after calcium induced activation of
calmodulin.

Mice deficient in nNOS exhibited increased vulnerability to

ethanol-induced neurodegeneration, particularly in the cingulate cortex and
nuclei of the thalamus (Bonthius et al, 2006), which were the brain regions of
most interest to us.

In our experimental paradigm, nNOS levels were

significantly increased in tPA-/- mice, but not WT, 24 hrs after ethanol treatment
(Figure 13A and 13B).

This suggests that there might have been a

neuroprotective pathway in the tPA-/- mice that included both NGF and nNOS.
The immediate early gene c-fos encodes a transcription factor induced by
neuronal activity that is critical in regulating neuronal cell survival. Mice in
which c-fos expression is largely eliminated in the hippocampus show
decreased BDNF transcription and protein expression, more severe KA-induced
seizures, increased neuronal excitability and neuronal death than control mice
(Zhang et al, 2002). We found that 8 hours after treatment, when ethanol levels
in the circulation are still significantly elevated, the expression of cFOS was
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suppressed in the forebrain of WT mice (Figure 13C and 13D). The tPA-/- mice
showed elevated expression of cFOS after ethanol treatment (Figure 13C and
13D).
Another molecule of interest was the growth and plasticity associated protein
43 (GAP-43), a neuronal protein with a critical role in axon guidance during
synaptogenesis, as phosphorylation of GAP-43 on Ser41 by PKC promotes
cytoskeletal remodeling (Widmer and Caroni, 1993; Aigner et al., 1995).
Phosphorylated GAP-43 (Ser 41) was significantly increased above control
levels in the tPA-/-, but not in WT, 24 hrs after ethanol treatment (Figure 13A
and 13B).

However, total levels of GAP-43 remained unchanged in both

genotypes and treatment groups (data not shown).

These results suggest

ethanol is not properly inhibiting synaptic activity in the tPA-/- mice, as the
neuroprotective properties of these molecules depend on excitatory, calciumdependent signaling pathways. Consistent with our results, recent research
shows NMDA-induced currents were larger in tPA-/- cortical neurons than in
WT mice (Park et al, 2008), giving support to the idea that tPA regulates the
NMDA-R.
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Figure 13. Ethanol does not suppress synaptic activity markers in the
tPA-/- mice. WT and tPA-/- P7 mice were treated with ethanol or saline and
sacrificed 8 hrs and 24 hrs later. The brains were removed and the forebrains
homogenized and analyzed by western blot for cFOS expression 8 hrs after
ethanol treatment, and for phospho-GAP-43 and nNOS 24 hrs post-ethanol.
Baseline levels of all molecules were similar in both genotypes. Ethanol
significantly increased both phospho-GAP-43 and nNOS in the tPA-/-, but
not the in WT (A and B). The effect was stronger for nNOS (**, P < 0.001)
than phospho-GAP-43 (*, P < 0.05) in the tPA-/- brain. nNOS and phosphoGAP-43 remained the same after ethanol in the WT mouse.

cFOS

expression was evaluated 8 hrs after ethanol exposure (C). Expression of
cFOS was higher in the tPA-/- mouse than the WT (D) (*, P < 0.05).
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3.7 tPA promotes neurodegeneration via the NMDA-R
Ethanol decreases synaptic activity by a dual mechanism that involves
inhibition of the NMDA-R, and potentiation of the GABAA-R. To determine
which neurotransmitter system mediates tPA’s effects after ethanol, we injected
WT and tPA-/- mice with high doses of either Diazepam (30 mg/kg; GABAA-R
agonist) or MK801 (1.5mg/kg; non-selective antagonist of NMDA-R) and
analyzed neuronal loss 24 hours after injection.

As previously reported

(Ikonomidou et al, 2000), both Diazepam and MK801 treatment induced
extensive neuronal death in the developing WT cortex (Figure 14A, 14B, and
14I), and thalamus (Figure 14C, 14D, and 14I). tPA-/- mice showed neuronal
death after Diazepam in the cortex (Figure 14E and 14J) and thalamus (Figure
14G and 14J), though to a significantly lesser degree than the WT. tPA-/- mice
demonstrated neuroprotection after MK801 (Figure 14F, 14H, and 14J),
suggesting tPA effects on neurodegeneration are mediated by the NMDA-R.
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Figure 14. tPA promotes neurodegeneration via the NMDA-R. WT and
tPA-/- P7 mice were injected with the non-selective NMDA-R antagonist
MK801 (1.5mg/kg) or the GABAA-R agonist Diazepam (30mg/kg). Control
mice were injected with saline as (N = 6/group). 24 hrs after treatment,
animals were sacrificed and brain sections analyzed histologically with FJB
to visualize neurodegeneration.

Diazepam induced induced extensive

neuronal death in the cortex (A) and thalamus (C) of WT when compared to
saline-treated mice (***, P < 0.0001).

Diazepam also induced

neurodegeneration in the cortex (E) and thalamus (G) of tPA-/- mice, albeit to
a significantly lesser degree than WT mice. WT mice were also vulnerable
to NMDA-R-induced neurodegeneration since MK801 treatment resulted in
increased FJB-positive staining in the cortex (B) and thalamus (D) (***, P <
0.0001). tPA-/- mice, however, were significantly protected from NMDA-Rmediated neuronal death since MK801 did not increase FJB staining in the
cortex (F) or thalamus (H) of these mice (P > 0.05).
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Figure 14
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Since NR2B is the prominent NR2 subunit during synaptogenesis, and
results from prior studies suggest that tPA can interact with NR2B in the adult
brain (Pawlak et al, 2005; Norris and Strickland, 2007), we examined
neurodegeneration after treatment with the NR2B-specific antagonist Ro256981 (6mg/kg) in WT and tPA-/- P7 pups. Neurodegeneration was observed in
the cortex (Figure 15A and 15I) and thalamus (Figure 15C and 15I) of WT mice
after drug treatment.

tPA-/- mice were protected from Ro25-6981

neurodegeneration (Figure 15E, 15G, 15J). We wondered if a combination of
Ro25-6981 and ethanol would augment neurodegeneration in the WT mice.
Pups were treated with Ro25-6981 (6mg/kg) 30 minutes prior to treatment with
ethanol.

Ethanol potentiated Ro25-6981-induced neurodegeneration in the

cortex (Figure 15B and 15I) and thalamus (Figure 15D and 15I). Next, we
administered the same combination of treatments to the tPA-/- pups as an
attempt to potentiate inhibition of the NMDA-R neurotransmitter system in
these mice. tPA-/- mice were still protected from neurodegeneration even in
these conditions (Figure 15F, 15H, and 15J), suggesting tPA promotes
neurodegeneration via an NR2B-dependent mechanism.
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Figure 15. tPA-/- mice are resistant to NR2B-mediated neuronal death.
WT and tPA-/- P7 mice were injected with either a NR2B selective NMDAR antagonist Ro25-6981 (6mg/kg), a combination of Ro25-6981 (6mg/kg)
administered 30 mins prior to acute ethanol binge treatment (2.5g/kg at 0hr
and 2hr). Control mice were injected with saline as (N = 5/group). 24 hrs
after treatment, animals were sacrificed and brain sections analyzed
histologically with FJB to visualize neurodegeneration. Ro25-6981 induced
extensive neuronal death in the cortex (A) and thalamus (C) of WT when
compared to saline-treated mice (***, P < 0.0001). When Ro25-6981 was
administered with ethanol neurodegeneration was increased in the cortex (B)
and thalamus (D) (***, P < 0.0001). tPA-/- mice, however, were protected
from NMDA-R-mediated neuronal death after administration of Ro25-6981
on its own (E and G) or in combination with ethanol (F and H).
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Figure 15
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3.8 Ethanol differentially modulates the NMDA-R in WT and tPA-/- mice
Since

tPA-/-

mice

were

protected

from

NMDA-R-mediated

neurodegeneration, we determined the expression levels of individual NMDA-R
subunits in tPA-/- and WT P7 pups before and after ethanol treatment. Western
blot analysis of forebrain homogenates showed no differences in NR1
expression between genotypes before and after ethanol (Figure 16A and 16B).
NR2B baseline levels were also similar in tPA-/- and WT early postnatal aged 7
mice. (Figure 16A and 16C). However, NR2B was upregulated 24 hours after
ethanol-treatment in tPA-/- mice, but not wild type mice (Figure 16D and 16E).
Baseline NR2A levels were higher in the tPA-/- brain than in the WT (Figure
16F and 16G), and ethanol treatment further augmented NR2A expression in
the tPA-/- 24 hrs after treatment (Figure 16F and 16H). It has been postulated
that NR2A and NR2B can have different and opposing roles in the adult brain.
NR2A has been shown to activate survival-signaling pathways, whereas NR2B
activates cell death pathways (Liu et al, 2007). It might be possible then that at
P7, enhanced baseline NR2A expression, and subsequent ethanol-induced
increase in NR2B in the neonatal tPA-/- brain, may be part of the observed
neuroprotection from NMDA-R mediated antagonism.
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Figure 16. Ethanol differentially modulates the NMDA-R in WT and
tPA-/- mice. WT and tPA-/- P7 mice were injected with either ethanol or
saline, and the forebrain NMDA-R subunit composition analyzed by western
blot. WT and tPA-/- have no baseline differences in total NR1 or NR2B (A,
B, and C; P > 0.05). However, 24 hours after ethanol administration, NR2B
was significantly increased above the baseline in the tPA-/- but not WT
forebrain (D and E; ***, P < 0.0001). We found NR2A baseline levels were
higher in the tPA-/- than in the WT (G; *, P < 0.05), and ethanol further
increased NR2A in tPA-/- 24 hours after ethanol (F and H; *, P < 0.05).
While ethanol increased NR2A in the tPA-/-, it decreased the subunit
expression in the WT mice (H; *, P < 0.05). The effect of ethanol on NR2A
was contingent on the genotype of the animals (H; ***, P < 0.0001).
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Figure 16
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There are multiple mechanisms of NMDA-R regulation. The NR2B subunit
contains an adaptor protein complex (AP-2) binding site in its C-terminal
domain. AP-2 is a component of endocytic clathrin coated pits which regulate
cell surface expression of NR2B (Prybylowski et al, 2005). Binding of AP-2 to
NR2B is inversely related to the phosphorylation state of Y1472 residue by Src
kinases (Roche et al, 2001; Yaka et al, 2002). Therefore phosphorylation at this
residue leads to decreased AP-2 binding and enhanced NR2B surface
expression.

We explored the association of AP-2 to NR2B by

immunoprecipitating ß-adaptin, a component of the AP-2 complex, with an
NR2B antibody. We studied WT and tPA-/- mice before and after 6hrs and 24
hrs of ethanol exposure. We found that the association of ß-adaptin with NR2B
was unchanged from control levels in the tPA-/- brain at any of the studied
timepoints after ethanol (Figure 17).

WT mice however showed reduced

association of ß-adaptin 6 hrs after ethanol (Figure 17). However, a significant
enhancement of ß-adaptin association to NR2B was observed 24 hrs after
ethanol treatment (Figure 17). These findings suggest that ethanol’s blockade
of the NMDA-R led to increased receptor internalization, possibly leading to
impaired synaptogenesis and neurodegeneration in the WT brain.

The

decreased association of ß-adaptin 6 hrs after ethanol in the WT mice could be
due to a homeostatic mechanism induced to counterbalance inhibition of NR2B
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in the presence of ethanol. However, the reduced association observed at 24 hrs
is consistent with the decrease in circulating levels of ethanol and concomitant
with neurodegeneration. tPA-/- mice, however, did not show any changes in ßadaptin association to NR2B after ethanol (Figure 17), suggesting the stability
of the NMDA receptor complex was not affected by ethanol, and as a result the
establishment of new synaptic connections and cell survival processes was not
hindered.
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Figure 17. Ethanol modulates ß-adaptin association to NR2B in WT,
but not tPA-/- mice. WT and tPA-/- P7 mice were injected with ethanol or
saline and sacrificed 24 hours after treatment. Forebrain homogenates were
immunoprecipitated with an anti-NR2B antibody, and subsequently probed
for ß-adaptin to investigate whether ethanol affects NR2B subunit
internalization. We found ethanol significantly decreases the association of
ß-adaptin to NR2B 6 hours post administration (B; *, P < 0.05; **, P <
0.001) but this association was increased above the baseline 24 hours later.
ß-adaptin association to NR2B in the tPA-/- was unchanged at any time-point
after ethanol treatment.
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3.9 tPA-deficient mice were protected form cognitive defects induced by
early postnatal ethanol treatment
We evaluated the cognitive ability of adult mice (8-10 weeks of age) that were
exposed to ethanol or saline at P7. We found, consistent with previous reports
(Ieraci and Herrera, 2005), that WT mice that had undergone ethanol treatment
at P7 had approximately a 20% reduction in contextual fear conditioning
compared to the saline treatment group (Figure 18). In contrast, tPA-/- mice that
received ethanol at the same age did not show impairments when compared to
their saline-treated counterparts (Figure 18). Interestingly, there is a baseline
difference between WT and tPA-/- mice, since saline-treated tPA-/- animals
exhibited slightly decreased freezing (i.e increased locomotor activity) during
the contextual test when compared to WT saline-treated mice.

But this

reduction in freezing between WT and tPA-/- saline treated animals did not
reflect a lack of learning of the paradigm in the tPA-/- mice since contextual
freezing for these mice was significantly greater than that observed during
training. This suggests that exposure of the immature brain to a binge-like dose
of ethanol has long-term effects on the brain and as a result, on behavior. These
effects are commensurate to the vulnerability of the immature brain to ethanolinduced neurodegeneration, and support a role for tPA as a regulator of ethanolinduced neurodegeneration and FAS development.
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Figure 18. Neonatal exposure to ethanol induces learning and memory
deficits in WT, but not tPA-/- mice. WT and tPA-/- P60-90 that had been
treated with ethanol or saline at P7 were tested on the fear conditioning
paradigm. WT mice that had been treated with ethanol at P7 showed a
decrease in fear conditioning as observed by a 20% reduction in freezing
behavior when compared to WT mice that had been exposed to saline (*, P <
0.05). Ethanol did not induce differences in the adult tPA-/- mice, since
ethanol- and saline-treated mice showed similar freezing behavior.
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3.10 Ethanol treatment increased neuronal-associated tPA activity in
perinatal PAI-1-/- mouse pups
Since PAI-1, the main inhibitor for tPA in the brain, was regulated by
ethanol in WT mice we decided to investigate what role, if any, PAI-1 plays
in ethanol-induced neuronal death.

We subjected WT, tPA-/-, and PAI-1-/-

postnatal age 7 to the acute ethanol binge paradigm that serves as a model
for FAS in mice. Mice were injected as described earlier with ethanol at a
dose of 2.5g/kg at 0 and 2 hrs. Control mice were injected with equal
volumes of saline. We sacrificed mice at different time-points after ethanol
treatment, and visualized tPA activity in PAI-1-/- forebrain homogenates
using in-gel zymography. We found tPA activity was significantly increased
over 1.5-fold 30 mins and 1 hr (Figure 19A and 19B) after ethanol.
However, contrary to the long-lasting tPA increase observed in WT mice,
the increase in activity was reduced back to the baseline in the PAI-1-/- mice
8 hrs after ethanol, and continued to be decreased at 24 hours (data not
shown).
3.11 Ethanol modulates PAI-1 in a tPA-independent manner
Since PAI-1 levels were regulated by ethanol in the WT mice, we were
then interested in examining PAI-1 in the tPA-/- mice using an enzymelinked immunosorbent assay (ELISA). We were surprised to find out that
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tPA-/- mice have significantly higher baseline levels of PAI-1 than WT
(Figure 19C). Contrary to what was observed in the WT brain, ethanol
treatment did not enhance PAI-1 levels further in the tPA-/-. However, 24
hours after ethanol, PAI-1 was downregulated below the baseline for both
WT and tPA-/- mice, suggesting ethanol-induced modulation of PAI-1 occurs
independently of tPA. The results also raise the possibility that PAI-1 might
be involved in the ethanol response in the tPA-/- mice, possibly as a source of
neuroprotection.
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PAI-1 levels

Figure 19. Ethanol treatment increased tPA activity in perinatal PAI-1-/mouse pups, and modulated PAI-1 in a tPA-independent manner. WT,
tPA-/-, and PAI-1-/- P7 pups were injected with ethanol or saline as a control.
In-gel zymography revealed tPA activity is significantly increased in the
PAI-1-/- mice 0.5hr and 1 hr after ethanol exposure (A and B; **, P < 0.001).
ELISA of WT and tPA-/- homogenates showed baseline PAI-1 levels are
significantly higher in the tPA-/- when compared to WT mice (C; **, P <
0.001). PAI-1 levels were decreased below the baseline for both WT and
tPA-/- 24 hrs after ethanol, indicating ethanol-mediated modulation of PAI-1
occurs independently of tPA.
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3.12 PAI-1-deficient pups are more vulnerable to ethanol-induced
neurodegeneration
Since baseline levels of PAI-1 were higher in the tPA-/- animals, we
hypothesized PAI-1-deficient mice might be more vulnerable to ethanolinduced neurodegeneration.

We found that 24 hours after ethanol

administration PAI-1-/- mice showed enhanced neuronal death than WT
mice, as observed by increased FJB staining.

PAI-1-/- showed

neurodegeneration most prominently in the cerebral cortex (Figure 20A),
and in the thalamus (Figure 21A). Neurodegeneration in the cortex of PAI1-/- mice was close to 100-fold greater in the cortex (Figure 20G), and over a
100-fold in the thalamus (Figure 21G) of PAI-1-/- mice when compared to
WT. PAI+/- mice showed neurodegeneration similar to WT mice (Figure
20G and 21G). It was possible that the difference in neurodegeneration in
PAI-1-/- and WT could have been an artifact of differing blood ethanol
concentrations, perhaps reflective of underlying metabolic differences
between the two genotypes, and not to a primary difference in neuronal
physiology. To address this possibility, we determined the blood ethanol
concentrations following treatment.

We found no difference in blood

ethanol concentrations between PAI-1-/- and WT mice (Figure 22) at any
timepoint studied. This result verifies that the observed difference in the
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severity of neurodegeneration in the PAI-1-/- mice was not due to differences
in the rate of ethanol metabolism between mouse genotypes. These data
show that lack of PAI-1 exacerbates the neurotoxic effects of ethanol, and
provides support to the hypothesis that PAI-1 promotes neuronal survival
after ethanol exposure.
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Figure 20. PAI-1-deficient pups were more vulnerable to ethanolinduced neurodegeneration in the cortex. WT, tPA-/-, and PAI-1-/- P7
pups were injected with ethanol or saline, and sacrificed 24 hrs later to
determine neuronal death using FJB staining.

PAI-1-/- mice showed

increased neurodegeneration in the cortex when compared to WT treated
mice (A and C; *, P < 0.05).
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Figure 21. PAI-1-deficient pups were more vulnerable to ethanolinduced neurodegeneration in the thalamus. WT, tPA-/-, and PAI-1-/- P7
pups were injected with ethanol or saline, and sacrificed 24 hrs later to
determine neuronal death using FJB staining.

PAI-1-/- mice showed

increased neurodegeneration in the cortex when compared to WT treated
mice (A and C; *, P < 0.05).
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Figure 22. Blood ethanol concentrations are similar in WT and PAI-1-/-.
WT and PAI-1-/- P7 pups were injected with ethanol or saline as a control
(N=5/group). Mice were sacrificed at 0hr after treatment, and every 2 hrs
for the remaining 12 hrs after injection, trunk blood was collected, and
ethanol concentrations were obtained from plasma.

There were no

differences in ethanol levels between WT and PAI-1-/-, suggesting the rate of
metabolism was similar in both genotypes.

3.13 tPA promotes ethanol-induced neurodegeneration in PAI-1-/- mice
To determine whether the increased tPA activity seen in the PAI-1-/- brain
following ethanol treatment was associated with neuronal loss, we injected
i.p. PAI-1-/- pups with the small molecular weight inhibitor tPA-STOP
(10ug/g) 30 minutes before ethanol treatment. We have previously shown
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this drug can significantly decrease tPA activity both in vitro and in vivo
(Figure 7I and 7K), and consequently attenuated ethanol-induced
neurodegeneration in WT mice (Figure 7). PAI-1-/- mice pretreated with
tPA-STOP showed a significant attenuation of neurodegeneration after
ethanol as observed by decreased FJB staining (Figure 23). The number of
FJB-positive cells after ethanol was reduced ~100-fold, in both the cortex
(Figure 23B and 23E) and the thalamus (Figure 23D and E), in comparison
to PAI-1-/- animals treated only with ethanol (Figure 23A and 23C). These
findings indicate that tPA promotes ethanol-induced neurodegeneration in
the PAI-1-/- brain.
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Figure 23. tPA promotes ethanol-induced neurodegeneration in PAI-1-/mice. PAI-1-deficient P7 pups were administered different treatments: tPASTOP (10ug/g) 30 mins prior to acute binge ethanol, tPA-STOP alone, acute
binge ethanol alone, or saline control.

Pre-treatment with tPA-STOP

significantly attenuated ethanol-induced neurodegeneration as observed by
decrease FJB staining in both the cortex (B) and thalamus (D), when
compared to non-tPA STOP-treated ethanol exposed PAI-1-/- mice (A and C;
***, P < 0.0001).
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3.14 Ethanol decreased nNOS expression in PAI-1-/- mice
NO is produced by neuronal nitric oxide synthase (nNOS) after calcium
induced activation of calmodulin.

Mice deficient in nNOS exhibited

increased vulnerability to ethanol-induced neurodegeneration, particularly in
the cingulate cortex and nuclei of the thalamus (Bonthius et al, 2006). Since
ethanol increased nNOS expression in the tPA-/- mice suggesting it might be
part of a survival pathway that protects these mice from ethanol-induced
neurotoxicity, we evaluated nNOS levels in the PAI-1-/- brain after ethanol
treatment. Western blot analysis showed ethanol decreased below baseline
levels nNOS expression 24 hours after treatment in PAI-1-/- mice (Figure
24). The ethanol-induced reduction in nNOS in the PAI-1-/- mice was
significant when compared to WT and tPA-/- treated with ethanol (Figure
24). These results are consistent with the pro-survival role that has been
described for nNOS activity after ethanol exposure of the immature brain,
and concomitant with our neurodegeneration findings.
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Figure 24. Ethanol decreased nNOS expression in PAI-1-/- mice. Since
ethanol increased nNOS expression in the tPA-/- mice suggesting it might be
part of a survival pathway that protects these mice from ethanol-induced
neurotoxicity. We evaluated nNOS levels in the PAI-1-/- P7 mice after
ethanol treatment (N=4). Western blot analysis showed ethanol decreased
below baseline levels nNOS expression 24 hours after treatment in PAI-1-/mice (A). The ethanol-induced reduction in nNOS in the PAI-1-/- mice was
significant when compared to WT and tPA-/- treated with ethanol (B; *, P <
0.05; ***, P < 0.0001).
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3.15 PAI-1 promotes neuronal survival and tPA promotes neuronal
death after ethanol treatment
To investigate the potential role of PAI-1 in the neuronal protection from
ethanol-induced toxicity observed in tPA-/- mice, we developed mice that are
deficient in tPA and heterozygous for PAI-1 (i.e. tPA-/-:PAI-1+/-) by crossing
double knock-out (tPA-/-:PAI-1+/-) mice with tPA-/-.

Analysis of FJB-

positive staining revealed tPA-/-:PAI+/- mice are more vulnerable to
neurodegeneration than tPA-deficient mice, but less susceptible than WT
mice (Figure 25). Ethanol-induced neurodegeneration, as reflected by FJB
staining, was observed in the cortical (Figure 25A) and thalamic (Figure
25B) regions of tPA-/-:PAI+/-. These results suggest PAI-1 promotes neuronal
survival in tPA-/- mice after ethanol treatment, since lack of a PAI-1 allele,
which presumably results in reduced protein levels, is sufficient to enhance
neuronal death in the absence of tPA.
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Figure 25. PAI-1 promotes neuronal survival and tPA promotes
neuronal death after ethanol treatment.
To investigate the potential role of PAI-1 in the neuronal protection from
ethanol-induced toxicity observed in tPA-/- mice, we developed mice that are
deficient in tPA and hemizygous in PAI-1 (i.e. tPA-/-:PAI-1+/-). Analysis of
FJB-positive staining revealed tPA-/-:PAI+/- mice are more vulnerable to
neurodegeneration than tPA-deficient mice, but less susceptible than WT
mice. Ethanol-induced neurodegeneration, as reflected by FJB staining, was
observed in the cortical (A) and thalamic (B) regions of tPA-/-:PAI+/- (**, P <
0.001; ***, P < 0.0001). Figure 25 G shows PCR analysis used to determine
the genotype of the animals used in the experiment.
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3.16 Chronic stress increases hippocampal tPA activity in WT and PAI-1deficient adult mice
Chronic restraint stress causes hippocampal-dependent cognitive deficits that
are consistent with hippocampal structural changes. Chronic stress results in
the atrophy of dendritic spines, and decreased expression of NR1 and NR2B
subunits in the CA1 region that lead to impaired learning of the Morris water
maze task in WT mice. tPA-/- mice are protected from these stress-induced
molecular, structural and behavioral effects (Pawlak et al, 2005). In addition,
PAI-1, has also been shown to be modulated by stress (Norris and Strickland,
2007). To investigate whether chronic stress leads to increased tPA activity in
the hippocampus, adult WT and PAI-1-/- mice were restrained 6 hours a day for
21 days, and sacrificed the following morning after the end of stress. Increased
extracellular tPA activity was observed via in situ zymography in the
hippocampus of WT and PAI-1-/- mice that had been chronically stressed
(Figure 26). The area of lysis (indicative of tPA activity) was increased 200%
in the WT mice that had been chronically stressed over the non-stressed levels
(Figure 26A and B). The increase in area of lysis observed in the PAI-1-/- mice
exceeded 200% (Figure 26C and D), when compared to non-stressed animals of
the same genotype.
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Figure 26. Chronic stress increases hippocampal tPA activity in WT
and PAI-1-/- mice.

To investigate if chronic stress regulates hippocampal

tPA, adult WT and PAI-1-/- mice were restrained for 21 days and sacrificed
on day 22 following the end of stress. The brains were sectioned and
analyzed for extracellular tPA activity. Increased tPA activity was observed
in the mossy fiber pathway of the hippocampal formation of chronically
restrained WT and PAI-1-/- mice (A and C). Stress increased the area of
lysis in the hippocampus from ~20% to ~40% in both genotypes (B and D;
***, P < 0.0001).
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3.17 Chronic stress decreases hippocampal PAI-1 levels in WT mice
Since chronic stress increased extracellular tPA activity in the hippocampus
of WT and PAI-1-/- mice, we investigated if PAI-1 is also regulated by chronic
stress. Upon completion of 21 days of restraint, stressed and non-stressed WT
mice were sacrificed and PAI-1 levels in hippocampal homogenates were
determined using an ELISA. Chronic stress significantly decreased by 200%
total PAI-1 antigen when compared to non-stressed WT mice (Figure 27).

Figure 27. Chronic stress decreased hippocampal PAI-1 levels in WT
mice. To further determine if stress modulates the tPA/PAI-1 system, we
analyzed PAI-1 levels in the hippocampus of chronically restrained WT
mice with ELISA.

Results indicate PAI-1 levels were significantly

decreased after chronic stress (*, P < 0.05).
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3.18 Chronic stress decreases fear conditioning in WT and PAI-1-/- mice,
but not in tPA-/To investigate whether the stress-induced changes in tPA activity and PAI-1
result in changes in learning and memory, we tested WT, tPA-/-, and PAI-1-/adult animals in fear conditioning. Animals were restraint stressed for 21 days,
or non-stressed as controls, and upon completion of restrain the mice were
tested in fear conditioning. Baseline freezing behavior to the conditioning
chambers was measured on the first day of the protocol, before starting the
conditioning to electrical shocks.

There were no differences in baseline

freezing between genotypes (Figure 28).

When animals were tested for

contextual conditioning on the second day, chronically stressed WT and PAI-1-/mice showed ~ 20% decrease in freezing when compared to their non-stress
counterparts, reflective of impaired learning and/or memory probably due to
chronic stress.

Restraint stressed tPA-/- mice did not show differences in

freezing behavior when compared to non-stressed tPA-/- controls. Also, tPA-/mice appear to be naturally more hyperactive than WT and PAI-1-/-. Nonstressed tPA-/- mice show reduced contextual freezing when compared to nonstressed WT and PAI-1-/-.
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Figure 28. Chronic restraint impairs contextual fear conditioning in WT
and PAI-1-/- mice but not tPA-/-. Adult WT, PAI-1-/-, and tPA-/- mice that
had been chronically restrained or non-restrained (control) were tested on
fear conditioning. Stressed WT and PAI-1-/- show a significant reduction in
freezing behavior when compared to the non-stressed animals of the same
genotype (**, P < 0.001). Stress did not have an effect on the tPA-/- mice.
Furthermore, there were basal differences in freezing between the nonstressed WT and PAI-1 when compared to non-stressed tPA-/- (***, P <
0.0001).

92

CHAPTER 4: DISCUSSION
4.1 Ethanol and neurotoxicity in a murine model of FAS
FAS is a prevalent disease in our society and there is currently no cure,
other than prevention, for this life-long affliction. The effects of ethanol on
the developing brain are particularly important because these often result in
behavioral and cognitive complications that not only have a serious impact
on the individual, but also place a burden on society. It is speculated that the
behavioral sequelae, and specifically the cognitive deficits that are
associated with FAS originate from brain mass loss and massive forebrain
neurodegeneration resulting from high doses of ethanol.

Therefore we

sought to determine whether tPA is a component of the molecular cascade
leading to neuronal death.
The data presented in this study identify tPA as a key molecular regulator
of the neurotoxic effects of alcohol in a well-accepted murine model of FAS
(Ikonomidou et al, 2000; Ieraci and Herrera, 2006; Maas et al, 2005; Heck et
al, 2008). We found tPA signaling is upstream of the apoptotic cascade and
of the NMDA-R. Our results also suggest tPA does not require proteolysis
or plasmin activation to induce neurodegeneration after ethanol. Except for
mice that are deficient in core apoptotic molecules (e.g BAX), no other
transgenic mouse line has shown resistance to the ethanol-induced
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neurotoxicity and the subsequent cognitive deficits that are characteristic of
FAS.
Furthermore, our data implicates the major inhibitor for tPA in the brain,
PAI-1, as an important regulatory component of neuronal survival after
ethanol.

In our model of FAS, PAI-1-/- mice were more vulnerable to

neurodegeneration than WT after ethanol treatment. Our data indicate PAI-1
can provide trophic support to neurons in the presence of ethanol, tPA-/-:
PAI-1+/- mice are more susceptible to neurodegeneration after ethanol than
tPA-deficient animals.

4.2 Ethanol modulates tPA activity and PAI-1 expression in WT pups
We found that postnatal day 7 WT mice exposed to acute-binge ethanol
showed changes in tPA activity and PAI-1 expression. Ethanol treatment
elevated tPA activity for a period close to 24 hrs. tPA up-regulation was
accompanied by an increase in PAI-1 levels. PAI-1 expression, however,
was increased for less than 6 hrs after ethanol. Interestingly, PAI-1 was
downregulated below baseline levels at 24 hours, suggesting ethanol
modulation of PAI-1 is independent of tPA activity. It is probable the
increase in PAI-1 observed after ethanol was not sufficient to counterbalance
the increase in tPA, and consequently interfere with its activity and/or
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interactions. Moreover, PAI-1 modulation after ethanol exposure occurred
independently of changes in tPA activity, which favored the hypothesis of a
tPA-independent modulation of PAI-1 after ethanol exposure.

4.3 tPA-/- mice are resistant to ethanol-induced apoptotic signaling and
neurodegeneration
Imaging studies of humans with FAS show a high incidence of
microencephaly (Swayze et al, 1997), reductions in cortical gray matter and
total brain volumes (Rivkin et al, 2008), decreased size of the basal ganglia
(Mattson et al, 2006), and abnormal development or in some cases absence
of the corpus callosum (Bookstein et al, 2002). In our experiments, WT
mice showed over a 100-fold increase in FJB staining in the thalamus and
cortex when compared to the saline-treated control mice. In comparison,
tPA-deficient mice showed less than a 4-fold increase in FJB staining after
ethanol. Concomitantly, activation of caspase-3, a key effector molecule in
the apoptotic cascade, was observed in WT, but not tPA-/-, confirming the
results observed with FJB. The effects of tPA appeared to be dependent on
gene-dosage since hemizogous tPA mice (tPA+/-), which probably exhibit
reduced production of tPA in the brain, showed intermediate susceptibility to
neuronal death between what was observed in the WT and tPA-/- animals.
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Furthermore, since blood ethanol levels were similar in WT and tPA-/animals after treatment, we concluded the effects of tPA on ethanol-induced
neurodegeneration were not due to underlying differences in the rate of
metabolism, but on the acute effects of tPA on neuronal physiology. In
addition, ethanol treatment resulted in plasma concentrations that were
consistent with the criteria required to induce neurodegeneration
(Ikonomidou et al, 2000). In addition, there were no obvious differences in
the time of loss of righting reflex after ethanol between WT and tPA-/- mice
(personal observation), supporting that rate of ethanol metabolism is not the
underlying

mechanism

for

tPA-mediated

ethanol-induced

neurodegeneration.

4.4 tPA-induced neurodegeneration after ethanol is independent of
proteolysis and plasmin production
Since tPA involvement in excitotoxic neuronal death is contingent on
plasminogen activation (Tsirka et al, 1995), we investigated ethanol-induced
neurodegeneration in plasminogen-deficient animals. We found Plg-/- mice
were just as vulnerable to ethanol-induced neurotoxicity as WT mice,
suggesting a plasmin-independent pathway was activated in tPA-mediated
neuronal death. Indeed, in the brain tPA can function independently of the
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typical plasminogen/plasmin proteolysis cascade through the modulation of
the NMDA-R or stimulation of the LRP receptor (Pawlak et al, 2005; Norris
and Strickland, 2007; Wang et al, 2003). It was reported tPA can directly
cleave the NR1 subunit of the NMDA-R leading to increased calcium influx
and excitotoxicity (Nicole et al, 2001). However, our laboratory has not
been able yet to replicate this finding. Our data suggest tPA proteolytic
activity is not a requirement to promote ethanol-induced neurodegeneration.
The catalytically inactive S481A tPA, when administered to tPA-deficient
mice, partially restored ethanol-induced neurodegeneration. The attenuation
in neurodegeneration observed after tPA-STOP treatment might arise from
preclusion of tPA-PAI-1 acyl-enzyme complex formation and downstream
LRP interactions. It is also possible that association of tPA-STOP to tPA
might have altered protease interactions with the NMDA-R or LRP, which
has been reported to mediate a tPA-induced increase in matrix
metalloproteinase-9 (MMP-9) resulting in neuronal death (Wang et al, 2003;
Hu et al, 2006), or with a yet to de described binding partner.

Future

research will address the nature of tPA’s interactions and signaling partners
in ethanol-induced neurodegeneration.
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4.5 tPA-mediated ethanol-induced neurodegeneration occurs via the
NMDA-R
The NMDA-R is critical during development particularly since excitatory
signaling is crucial for the formation of new synaptic contacts. During brain
development, up to 25% of the neuronal population is eliminated in early
postnatal stages during synaptogenesis (for reviews see Hidalgo et al, 2003;
Benn and Woolf, 2004). Blockade of the NMDA-R exacerbates the basal
rate of apoptosis that occurs developmentally, consequently impairing the
appropriate formation of synapses, and eventually of neuronal circuitry
(Ikonomidou et al, 1999 and 2000; Ghiani et al, 2007). Our data suggest
ethanol and, NMDA-R antagonists MK801 and Ro25-691, do not obliterate
NMDA-R-dependent function in tPA-/- mice. Interestingly, basal NMDA-R
function might have been more robust in the tPA-/- mice since increased
NR2A expression was observed in these mice when compared to WT.
Consistent with our results, enhanced basal NMDA-R currents in tPA-/slices were observed in adult animals (Park et al, 2008). It remains unclear
what the underlying cause is for increased excitatory signaling in these mice.
Additionally, NMDA-R function in the tPA-/- mice might have been
further enhanced as a result of ethanol exposure. tPA-deficient animals
showed elevated NR2B, NR2A, BDNF, NGF, and nNOS, 24 hours post
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ethanol administration. These are proteins that function downstream of the
NMDA-R and are dependent on calcium signaling.

Ethanol also up-

regulated the expression of the activity-dependent immediate early gene
cFOS 8 hours post-treatment in the tPA-/-, but not WT mice which suggested
excitatory signaling was surprisingly improved or enhanced after ethanol.
Increased NR2A and NR2B might be responsible for downstream increases
in cFOS, nNOS, and neurotrophic factors.
In addition, western blot analysis of crude synaptosomal homogenates
showed reduced basal PSD-95 protein in the tPA-/- forebrain, consistent with
a previous study that found reduced association of PSD-95 with the NR2B
subunit of the NMDA-R (Norris and Strickland, 2007). These results are
incredibly fascinating, and support the hypothesis of tPA as a key modulator
of the receptor, perhaps enabling the appropriate interactions between NR2B
and PSD-95.

Indeed NR2B

-/-

mice die within the first week of birth

(Kutsuwada et al, 1996; Tovar et al, 2000), while PSD-95-/- mice survive
into adulthood (Kim et al, 2003) suggesting there might be other molecules
that are essential during early development.

A potential candidate is

synaptic ras GTPase-activating protein (SynGAP), and just like NR2B-/mice, SynGAP null mutants die early after birth (Komiyama et al, 2002).
Although SynGAP binds PSD-95 in the adult PSD, both genes have distinct,
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as well as overlapping expression. The expression of SynGAP in the murine
brain peaks during synaptogenesis and developmental plasticity in contrast
to PSD-95, which is expressed throughout the brain from early embryonic
stages. Furthermore, SynGAP shows a spatial pattern restricted mostly to
the forebrain in contrast to PSD-95, which is also found in mid- and
hindbrain (Porter et al, 2005). These report indicate that synaptic signaling
complexes are heterogeneous, and individual components show temporal
and spatial specificity during development, and might account for the
discrepancies observed between the neonatal WT and tPA-/- forebrain.
As discussed in the introductory section, the NR2 subunits undergo a
developmental shift after birth. NR2B is the predominant NR2 subunit at
birth and early post-natal stages. NR2A expression begins close to postnatal day 6, and slowly becomes the predominant subunit at the synapse,
displacing most of NR2B to extrasynaptic sites (Sheng et al, 1994; Liu et al,
2004). NR2A-containing receptors promote neuronal survival while NR2Bcontaining receptors promote apoptosis in adult neurons. The mechanism for
NR2A-mediated survival depends on the activation of the Akt pathway, and
this molecular cascade involves NO (Liu et al, 2007). Synaptic NMDA-R
activation leads to the stimulation of the cAMP response element binding
(CREB) and extracellular signal-regulated kinase (ERK), whereas
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extrasynaptic NMDA-R stimulation leads to shutoff of the CREB pathway
(Hardingham et al, 2002).

In cerebellar granule neurons, NO-mediated

survival after ethanol-induced neurodegeneration required CREB activation
and NGF, which we found was increased in the “ethanol-resistant” tPA-/brain.

Consistent with our data, neonatal nNOS-deficient mice showed

increased neurodegeneration after ethanol in the same FAS paradigm we
used in our studies (Bonthius et al, 2006). And ethanol-induced increase in
nNOS and NGF, which are in the same neuroprotective pathway (Bonthius
et al, 2003 and 2006), was observed in the tPA-/- mice. Enhanced NR2A in
the tPA-/- brain, as opposed to the decreased observed in the WT, might have
engaged downstream signaling molecules like NO and NGF thus serving as
a starting advantage against neurotoxicity from ethanol.
We also observed increased association of the clathrin-associated ßadaptin to the NR2B subunit of ethanol-treated WT 24 hours after treatment.
We did not observe changes in the tPA-/- mice after ethanol. Clathrinmediated endocytosis serves as a regulatory mechanism for NMDA-R
surface expression and function (Lavezzari et al, 2004).

Our

immunoprecipitation results suggest increased clathrin-mediated endocytosis
of the NMDA-R complex after ethanol exposure.
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The observed reduction

in NR2A in conjunction to endocytosis of NR2B-containing receptors in the
WT mice after ethanol might underlie neurodegeneration after treatment.

4.6 tPA-/- mice have increased neurotrophic factor expression
A “neurotrophic theory” has been proposed based on data from the
sympathetic and motor nervous system (Linden 1994; Sendtner, 2000)
where the select subset of neurons that survive during synaptogenesis do so
via connection to appropriate targets that supply them with neurotrophic
factors. This model of activity-dependent survival comes from in vivo and
in vitro studies where cortical neurons have shown dependence on the
activation of the NMDA-R and the consequent synthesis/release of BDNF
for survival (Lessman et al, 2003; Suzuki et al, 2007). tPA-/- mice showed
enhanced expression of BDNF and NGF 24 hrs after ethanol. It is likely the
increase in these proteins began at an earlier time-point and provided a
source of trophic support from ethanol toxicity. Furthermore, it is likely the
changes in these proteins in the tPA-/- arise from initial changes observed in
the NMDA-R subunit composition.
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4.7 Neonatal ethanol-induced neurodegeneration leads to adult cognitive
impairments
Early exposure to ethanol interferes with the formation of synaptic
contacts possibly affecting the later development of neural circuits. The
cortex, thalamus, and hippocampus, which comprise part of the limbic
system, are some of the most vulnerable brain regions to ethanol-induced
neurodegeneration during synaptogenesis. Consistent with previous reports,
we show that neonatal exposure of the WT brain, but not tPA-/-, to ethanol
results in decreased contextual fear conditioning, a learning task that
depends on intact hippocampal function (Chen et al, 1996). Indeed, the
hippocampus is essential for memory storage, and the thalamus, typically
referred to as the relay station of the brain, allows communication between
the cortex and other brain regions, including the hippocampus. Therefore, it
was

not

unexpected

that

ethanol-induced

neurodegeneration

was

commensurate with the behavioral deficits observed in the WT mice.

4.8 tPA is a key regulator of ethanol-induced neurodegeneration and
FAS development
Overall, our data suggests a novel role for the NMDA-R in
neuroprotection from ethanol’s effects that are opposite from what is
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observed during excitotoxicity. Increased basal levels of NR2A in the tPA-/brain might be an advantageous starting point through which the NMDA-R
compensates the blockade of ethanol. The advantage that increased NR2A
might provide to the tPA-/- brain is probably enhanced by increased NR2B
and NR2A at a later timepoint in the presence of ethanol. These NR2
subunit differences, and, subsequent changes after ethanol probably boost
NMDA-R function, nNOS-dependent signaling, and neurotrophic factor
support.

In fact, nNOS has been shown to protect cultured cerebellar

neurons from ethanol-induced death via the PKG pathway and NGF
production. So it is possible that increased NR2A and NR2B can lead to
downstream changes such as enhanced nNOS activity, and increased
neurotrophic signaling that protects cells from the toxic effects of ethanol.
It still remains unclear what the trigger for the increased tPA in the WT
brain might be. Ethanol depresses synaptic activity through inhibition of the
NMDA-R and the GABAA-R. However, tPA is not a constitutively secreted
protease, it is synthesized and stored in synaptic vesicles in axon terminals,
and released into the extracellular space upon depolarization (Gualandris et
al, 1996). In the adult brain, the answer to ethanol-induced increase in tPA
might lie in the NMDA-R since chronic exposure stimulates the production
of more receptors, probably as a compensatory mechanism from ethanol-
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induced inhibition. As a result, tPA was also increased, and its interaction
with the NR2B subunit was found necessary for ethanol-induced NMDA-R
upregulation (Pawlak et al, 2005), thus leading to a positive feedback
mechanism between the NMDA-R and tPA that was initially stimulated by
ethanol. However, this mechanism does not account for what we observed
in our model with neonatal animals, since we did not observe any evidence
of ethanol-induced NMDA-R stimulation in the WT brain. An explanation
could lie in the cellular source of increased tPA in the brain after acute
ethanol exposure. Besides neurons, tPA is also synthesized by microglia
cells in the brain (Rogove et al, 1999), and these cells can also be activated
by tPA independently of proteolysis.

As a result, the ethanol-induced

increase in tPA we observe could be partly due to microglia activation. This
is consistent with our findings that suggest tPA induces neurodegeneration
after ethanol independently of plasminogen and proteolytic activity. An
experiment could evaluate neuronal death after the administration of ethanol
to neonatal mice that are deficient in neuronal- or microglial-specific tPA.
Furthermore, microglia involvement is likely to only be part of the
explanation since we observed many basal and ethanol-induced differences
in NMDA-R subunit composition, NMDA-R-dependent signaling, and PAI1 involvement between WT and tPA-/- mice.
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Our study shows tPA is a novel molecule crucial in the development of
FAS.

Exposure of neonatal mice to ethanol leads to widespread

neurodegeneration, prolonged increase in tPA activity in WT mice, and
cognitive impairments in adult animals. tPA-/- mice however do not undergo
neurodegeneration

or

develop

subsequent

cognitive

impairment

characteristic of FAS. The pharmacological manipulation of tPA levels in
the brain might be a therapeutic avenue for the treatment of FAS and
NMDA-R blockade related pathologies.

4.9 Ethanol treatment increased neuronal-associated tPA activity in
perinatal PAI-1-/- mouse pups
PAI-1 serves as the major inhibitor of tPA in the brain and as such is an
important regulatory component of the tPA/plasmin pathway that is engaged
in excitotoxicity (Tsirka et al, 1996). We have shown here that ethanol
exposure during synaptogenesis differentially modulates tPA activity and
PAI-1 levels in the forebrain of WT neonatal P7 mice. Ethanol induced a
prolonged increase in tPA activity and temporarily upregulated PAI-1 soon
after treatment. Levels of PAI-1, however, were downregulated 24 hrs after
ethanol exposure. Since PAI-1 was regulated by ethanol in WT mice, we
were interested in evaluating tPA activity in PAI-1-deficient animals.
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Ethanol treatment increased tPA activity in the forebrain of PAI-1-/- mice,
but contrary to what is observed in WT, the observed increase in tPA was
rapid and short-lasting. Though the timeline for increased tPA activity is
slightly different in WT and PAI-1-/- mice, the increase in tPA in both
genotypes

precede

the

activation

of

caspase-3

and

consequently

neurodegeneration, suggesting tPA is an important component of the
neurodegenerative cascade after ethanol in PAI-1-/- mice.

4.10 Ethanol modulates PAI-1 in a tPA-independent manner
PAI-1 modulation by ethanol had been previously observed in cultured
human endothelial cells where ethanol treatment induced a transcriptional
decrease of PAI-1 mRNA (Grenett et al, 2000). In our acute binge paradigm
that serves as a model for FAS, ethanol initially increased, and progressively
decreased PAI-1.

The effects observed in PAI-1 after ethanol occur

independently of tPA, since tPA-/- mice showed a similar pattern of
modulation after ethanol exposure. Interestingly, we observed PAI-1
baseline levels were significantly greater in the tPA-/- mice than in WT, and
since tPA-/- mice are resistant to neurodegeneration, we hypothesized
elevated levels of PAI-1 might confer neuroprotection from ethanol toxicity
to these mice. The feasibility for this proposition is supported by studies
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that have implicated PAI-1 in neuritogenesis and neuronal survival (Kimura
et al, 2000; Soeda et al 2001; Guizzeti et al, 2008).

4.11 tPA promotes ethanol-induced neurodegeneration in PAI-1-/- mice
Indeed,

PAI-1-deficient

mice

showed

enhanced

vulnerability

to

neurodegeneration after ethanol exposure seen by increased FJB staining in
the cortical and thalamic regions of the forebrain in comparison to the WT
mice. It was possible that the difference in neurodegeneration in PAI-1-/and WT could have been an artifact of differing blood ethanol
concentrations, perhaps due to underlying metabolic differences between the
WT and PAI-1-/- mice, and not to a primary difference in neuronal
physiology. To address this possibility, we determined the blood ethanol
concentrations following treatment.

We found no differences in blood

ethanol concentrations at any time-point studied, suggesting the differences
observed are not due to the rate of ethanol metabolism.
Enhanced neuronal death vulnerability after ethanol exposure was
partially dependent on increased tPA activity, since treatment with the
synthetic inhibitor tPA-STOP before EtOH exposure led to attenuation of
the severity of neurodegeneration in these animals. This evidence is not
surprising, since in addition to tPA, PAI-1 interacts with other molecules in
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the brain (e.g. uPA, vitronectin, and LRP). Our data suggests that PAI-1 is
acting independently of tPA, and an interaction of PAI-1 with any of these
molecules could potentially influence the effects of ethanol, additionally to
the effects stemming from increased tPA activity. Furthermore, these results
suggest that while tPA mediates ethanol-induced neurotoxicity, PAI-1
mediates a survival-signaling cascade that protects neurons from
neurodegeneration. As a result, absence of PAI-1 exacerbates the neurotoxic
insult by ethanol, supporting the hypothesis that PAI-1 promotes neuronal
survival after ethanol exposure.
What could be the mechanism for PAI-1 in neuronal survival? PAI-1 is
secreted by astrocytes and a potential mechanism could entail modifications
of the extracellular matrix that favor the extension of neurites, thus
abrogating the effects of ethanol on neuronal activity and consequently
synaptogenesis.

A recent report showed that PAI-1 upregulation was

deemed necessary for laminin- and fibronectin-mediated neuritogenesis and
the extension of neurites during development (Guizzeti et al, 2008). It is
unclear though, whether PAI-1 actions are dependent or independent of tPA
in this study.
Another possibility entails PAI-1 in neuronal anti-apoptotic signaling
(Kimura et al 2000 and Soeda et al 2001). These studies showed that PAI-1
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deficiency in NGF-differentiated PC12 cells resulted in a significant
reduction of Bcl-2 and Bcl-XL mRNAs, which typically promote cellular
survival, and an increase in Bcl-XS and Bax mRNAs, which typically
promote apoptosis (Soeda et al., 2001). As a result, changes in the balance
between mRNAs expressed by the anti- and pro-apoptotic Bcl-2 family
favored pro-apoptotic signaling, and resulted in cell death. Ethanol-induced
neurodegeneration in our model is apoptotic, and requires caspase-3
activation and cytochrome c release.

It might have been possible that

elevated levels of PAI-1 in the tPA-/- favored expression of anti-apoptotic
signaling molecules, thus protecting against ethanol-induced neuronal death
in these mice. Thus there are several scenarios through which PAI-1 might
be exerting neuroprotection, and future studies will address the mechanism
for PAI-1-mediated neuronal survival after ethanol in neonatal mice.

4.12 Ethanol decreased nNOS expression in PAI-1-/- mice
Previous studies have reported that PAI-1 can prevent serum
deprivation-induced loss of neurites in differentiated PC12 cells (Soeda et
al., 2004). In the same model system, it was later shown that adding PAI-1,
in the absence of NGF, can lead to the phosphorylation of Trk A receptors,
and promote neurite outgrowth and the survival of PC12 cells (Soeda et al,
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2006). In the presence of NGF, however, PAI-1 was found to act as a
synergist since the treatment of NGF-differentiated PC12 cells with anti-Trk
A receptor antibodies caused neurite disappearance and cell death. We’ve
shown tPA-/- mice are resistant to neurodegeneration, and concomitantly,
these mice show enhanced PAI-1, NGF, BDNF, and nNOS. WT mice,
however, have decreased NGF and PAI-1, and lack increased BDNF and
nNOS. A feasible mechanism for PAI-1-mediated neuroprotection could
then be through the synergistic activation of TrkA receptors with NGF.
Concomitantly, PAI-1 and NGF could promote neuroprotection from
ethanol toxicity through nNOS activation.

Particularly since the pro-

survival properties of nNOS after ethanol seem to require NGF (Bonthius et
al, 2003). nNOS was significantly up-regulated in the tPA-/- mice. However,
nNOS expression was unchanged in the WT, and significantly decreased in
the PAI-1-/- brain. These results are consistent with the pro-survival role that
has been described for nNOS activity after ethanol exposure of the immature
brain, and concomitant with our neurodegeneration findings. Decreased
nNOS expression in the PAI-1-/- brain after ethanol exposure, suggest nNOS
could be part of the neuroprotective pathway engaged by PAI-1 after
ethanol.
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4.13 PAI-1 promotes neuronal survival and tPA promotes neuronal
death after ethanol treatment
In order to further dissect the individual contributions tPA and PAI-1
have in neuronal death and survival after ethanol exposure, we created tPA-/:PAI-1+/- mice by crossing double knock outs with tPA-/- mice. We found
that ethanol-induced neurodegeneration in these mice was above what is
observed in the tPA-/-, but below WT levels. These mice do not make tPA
which makes them more resistant to neuronal death, but losing one allele of
the PAI-1 gene, which likely results in reduced expression of PAI-1 protein,
is sufficient to significantly increase neuronal death after ethanol. It is
possible the elevated levels of PAI-1 in the tPA-/- mice, in conjunction to the
lack of tPA, serve as an advantage and help protect neurons when exposed to
ethanol.

Further research into the trophic properties of PAI-1 during

neonatal brain development might lead open new therapeutic avenues for the
treatment of FAS-related pathologies.
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Figure 29. Model representing ethanol modulation of tPA and PAI-1 in
the neonatal brain. Early exposure of the brain to ethanol leads to changes
in tPA and PAI-1 that result in neurotoxicity. tPA-deficient animals are
resistant to ethanol-induced neurotoxicity, implicating tPA as a key regulator
of the effects of ethanol in the immature brain

We hypothesize that

abnormal differences in NMDA-R composition and function between WT
and tPA-/- mice underlies the changes observed in neurodegeneration. The
basal composition of the NMDA-R differs between WT and tPA-deficient
animals, with higher NR2A expression observed in the tPA-/- brain, possibly
serving as an advantageous starting point that protects against ethanol
toxicity. NR2A is further increased after ethanol in these mice but decreased
in the WT mice. Furthermore, ethanol increased the association of AP-2 to
NR2B in the WT, suggesting ethanol promoted the internalization of these
receptors in WT mice. Ethanol also increased neutrophic factor expression
in the tPA-/-, suggesting these molecules might serve as a source of
neuroprotection in the presence of ethanol. Lastly, PAI-1-/- mice were more
vulnerable to neurodegeneration, consistent with the observed increased
basal PAI-1 expression in the tPA-/- brain, suggesting increased PAI-1 in the
tPA-/- mice might preclude ethanol-induced neurodegeneration in these mice.
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Figure 29
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4.14 Ethanol exposure of the immature murine brain can lead to
learning deficits that are characteristic of FAS in humans
Prenatal exposure to ethanol leads to developmental defects in the brain
that often result in long-lasting behavioral complications, as is the case in
FAS. Neonatal P7 rodents that are exposed to binge-like doses of ethanol, as
we have done in our studies, leads to hyper-activity in the elevated plus
maze and open field, and impairment of contextual fear conditioning (Ieraci
and Herrera, 2006). Our results show that adult WT mice that had been
treated with ethanol at P7 have decreased contextual, but not cued, fear
conditioning. Adult tPA-deficient mice that had been treated with the same
dose of ethanol did not show differences in fear conditioning when
compared to saline-treated tPA-/-. These results are consistent with previous
reports, and support a causal link between ethanol-induced neuronal death
with the cognitive impairments that are observed in patients with FAS.
Furthermore, these results suggest that therapeutic agents that block, or
attenuate ethanol-induced neurodegeneration, might also be able to prevent
the cognitive deficits and possibly the development of other behavioral
disturbances that stem from ethanol exposure.
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4.15 Chronic stress regulates hippocampal-dependent behavior via
modulation of the tPA/PAI-1 system
tPA has multiple effects in the physiology of the CNS. In particular, tPA
modulates synaptic plasticity events that underlie several forms of learning
and memory of spatial memory tasks, LTP, and addiction. Furthermore, tPA
is modulated by stress in the hippocampus and amygdala (Pawlak et al, 2003
and 2005). The stress-induced increase observed in tPA activity in the
amygdala is mediated by the stress neuromodulator corticotropin releasing
factor (CRF) acting via corticotropin releasing factor receptor type 1 (CRF1) (Matys et al, 2004). tPA-deficient mice exhibit reduced anxiety-like
behavior to CRF but undergo a sustained corticosterone response after CRF
administration. These studies establish tPA as an important mediator of
cellular, behavioral, and hormonal responses to CRF, and consequently
stress.
We focused on the effects of stress on the hippocampal formation.
Previous reports from our laboratory showed chronic stress differentially
affected hippocampal NMDA-R expression, dendritic arborization, and
Morris water maze learning in WT and tPA-/- mice (Pawlak et al, 2005). We
found 21 days of restraint stress significantly elevated extracellular tPA
activity in WT and PAI-1-/-. Simultaneously, chronic stress had the opposite
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effect on PAI-1 levels, reducing it below the baseline in WT mice.
Furthermore, these changes observed in tPA and PAI-1 were reflected
behaviorally, as WT and PAI-1-/- animals that had been chronically stressed
showed decreased contextual, but not cued, fear conditioning. Chronically
stressed tPA-/- animals did not undergo changes in either contextual or cued
fear conditioning. These data are consistent with the lack of hippocampal
atrophy observed in the tPA-/- mice. Furthermore, they implicate PAI-1 as a
modulator of the stress response in the hippocampus.

It is likely that

decreased hippocampal levels of PAI-1 in the WT, and the lack of PAI-1 in
the PAI-1-/- mice, underlie the observed increase in tPA activity. It might be
possible the prolonged and elevated levels of tPA due to chronic stress lead
to detrimental changes in the molecular composition of the extracellular
matrix that contribute to neuronal atrophy. Increased tPA might also result
in degradation of the NMDA-R.

Plasminogen-deficient mice show a

phenotype similar to that observed in tPA-/- animals (Pawlak et al, 2005),
suggesting tPA acts via plasmin activation after chronic stress. Since tPAderived plasmin can cleave the NR1 subunit of the NMDA-R (Matys and
Strickland, 2003) we can speculate this could be an attractive mechanism for
tPA action after stress. Increased NR1 cleavage by plasmin could underlie
the reduction in NMDA-R observed at the end of chronic stress (Pawlak et

117

al, 2005). Furthermore, cleavage of NR1 could result in increased calcium
influx and stimulate excitotoxicity and neuronal death. Overall, these data
support a role for the tPA/PAI-1 system as key regulators of the cellular and
behavioral response to chronic stress stimuli.

118

REFERENCES
Aguado F, Carmona MA, Pozas E, Aguilo A, Martinez-Guijarro FJ,
Alcantara S, Borrell V, Yuste R, Ibanez CF, Soriano E. BDNF regulates
spontaneous correlated activity at early developmental stages by increasing
synaptogenesis and expression of K+/Cl- co-transport. Development (2003)
130: 1267-1280.
Ahern GP, Klyachko VA, Jackson MB. cGMP and S-nitrosylation: two
routes for modulation of neuronal excitability by NO. Trends Neurosci
(2002) Oct; 25(10):510-7.
Aigner, L; Arber, S; Kapfhammer, JP; Laux, T; Schneider, C; Botteri, F;
Brenner, H-R; Caroni, P. Overexpression of the neural growth-associated
protein GAP-43 induces nerve sprouting in the adult nervous system of
transgenic mice. Cell (1995) 83:269–278.
Andoh T., Lee S. Y. and Chiueh C. C. Preconditioning regulation of bcl-2
and p66shc by human NOS1 enhances tolerance to oxidative stress. FASEB
J (2000) 14: 2144–2146.
Atochin DN, Clark J, Demchenko IT, Moskowitz MA, Huang PL. Rapid
cerebral ischemic preconditioning in mice deficient in endothelial and
neuronal nitric oxide synthases. Stroke (2003) May; 34(5):1299-303.

119

Awobuluyi M, Yang J, Ye Y, Chatterton JE, Godzik A, Lipton SA, Zhang D
Subunit-specific Roles of Gycine-Binding Domains in Activation of
NR1/NR3 "NMDA" Receptors. Mol Pharmacol. (2007) Jan;71(1):112-22.
Baranes D, Lederfein D, Huang YY, Chen M, Bailey CH, Kandel ER.
Tissue plasminogen activator contributes to the late phase of LTP and to
synaptic growth in the hippocampal mossy fiber pathway. Neuron (1998)
21:813–25.
Benchenane K, López-Atalaya JP, Fernández-Monreal M, Touzani O,
Vivien D. Equivocal roles of tissue-type plasminogen activator in strokeinduced injury. Trends Neurosci. (2004) Mar;27(3):155-60.
Benn SC and Woolf CJ. Adult neuron survival strategies--slamming on the
brakes. Nature Reviews. Neuroscience (2004) 5(9):686-700.
S. Bennur, B.S. Shankaranarayana Rao, R. Pawlak, S. Strickland, B.S.
McEwen and S. Chattarji, Stress-induced spine loss in the medial amygdala
is mediated by tissue-plasminogen activator. Neuroscience (2007) 144: 8–
16.
Bonthius DJ, Karacay B, Dai D, Pantazis NJ. FGF-2, NGF and IGF-1, but
not BDNF, utilize a nitric oxide pathway to signal neurotrophic and
neuroprotective effects against alcohol toxicity in cerebellar granule cell
cultures. Brain Res Dev Brain Res. (2003) Jan 10;140(1):15-28.

120

Bonthius DJ, Karacay B, Dai D, Hutton A, Pantazis NJ. The NO-cGMPPKG pathway plays an essential role in the acquisition of ethanol resistance
by cerebellar granule neurons. Neurotoxicol Teratol. (2004) JanFeb;26(1):47-57.
Bonthius DJ, McKim RA, Koele L, Harb H, Kehrberg AH, Mahoney J,
Karacay B, Pantazis NJ. Severe alcohol-induced neuronal deficits in the
hippocampus and neocortex of neonatal mice genetically deficient for
neuronal nitric oxide synthase (nNOS). J Comp Neurol. (2006) Nov
10;499(2):290-305.
Bonthius DJ, Tzouras G, Karacay B, Mahoney J, Hutton A, McKim R,
Pantazis NJ. Deficiency of neuronal nitric oxide synthase (nNOS) worsens
alcohol-induced microencephaly and neuronal loss in developing mice.
Brain Res Dev Brain Res. (2002) Sep 20;138(1):45-59.
Bookstein FL, Streissguth AP, Sampson PD, Connor PD, Barr HM. Corpus
Callosum Shape and Neuropsychological Deficits in Adult Males with
Heavy Fetal Alcohol Exposure. Neuroimage. (2002) Jan;15(1):233-51.
Bozdagi O, Rich E, Tronel S, Sadahiro M, Patterson K, Shapiro ML,
Alberini CM, Huntley GW, Salton SR. The neurotrophin-inducible gene Vgf
regulates hippocampal function and behavior through a brain-derived
neurotrophic factor-dependent mechanism. J Neurosci. (2008) Sep
24;28(39):9857-69.

121

Bredt DS, Snyder SH. Nitric oxide mediates glutamate-linked enhancement
of cGMP levels in the cerebellum. Proc Natl Acad Sci USA (1989)
Nov;86(22):9030-3.
Brenman JE, Chao DS, Gee SH, McGee AW, Craven SE, Santillano DR,
Wu Z, Huang F, Xia H, Peters MF, Froehner SC, Bredt DS. Interaction of
nitric oxide synthase with the postsynaptic density protein PSD-95 and
alpha1-syntrophin mediated by PDZ domains. Cell (1996) Mar 8;84(5):75767.
Bruno MA and Cuello AC. Activity-dependent release of precursor nerve
growth factor, conversion to mature nerve growth factor, and its degradation
by a protease cascade. Proc Natl Acad Sci U S A. 2006 April 25; 103(17):
6735–6740.
Buisson A, Nicole O, Docagne F, Sartelet H, MacKenzie ET & Vivien D.
Up-regulation of a serine protease inhibitor in astrocytes mediates the
neuroprotective activity of transforming growth factor-beta1. FASEB J
(1998) 12: 1683−1691.
Buss RR, Gould TW, Ma J, Vinsant S, Prevette D, Winseck A, Toops KA,
Hammarback JA, Smith TL, and Oppenheim RW. Neuromuscular
development in the absence of programmed cell death: phenotypic alteration
of motoneurons and muscle. J Neurosci (2006) 26(52):13413.

122

Butt AM, Jones HC, Abbott J. Electrical resistance across the blood-brain
barrier in anaesthetized rats: a developmental study. J Physiol. (1990)
429:47-62.
Calabresi P, Centonze D, Bernardi G. Electrophysiology of dopamine in
normal and denervated striatal neurons. Trends Neurosci (2000) 23:S57-S63
Cameron and E. Gould, Adult neurogenesis is regulated by adrenal steroids
in the dentate gyrus, Neuroscience (1994) 61: 203–209.
Cao C, Lawrence DA, Li Y, Von Arnim CA, Herz J, Su EJ, Makarova A,
Hyman BT, Strickland DK, Zhang L. Endocytic receptor LRP together with
tPA and PAI-1 coordinates Mac-1-dependent macrophage migration. EMBO
J. (2006) May 3;25(9):1860-70.
Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De
Vos R, van den Oord JJ, Collen D, Mulligan RC. Physiological
consequences of loss of plasminogen activator gene function in mice. Nature
(1994) 368:419–24.
Cerqueira JJ, Pego JM, Taipa R, Bessa JM, Almeida OF, and Sousa N.
Morphological correlates of corticosteroid-induced changes in prefrontal
cortex-dependent behaviors, J. Neurosci. (2005) 25:7792–7800.
Chen C, Kim JJ, Thompson RF, Tonegawa S. Hippocampal lesions impair
contextual fear conditioning in two strains of mice. Behavioral
Neuroscience. (1996) 110(5):1177-1180.
123

Chen, ZL; Strickland, S. Neuronal death in the hippocampus is promoted by
plasmin-catalyzed degradation of laminin. Cell (1997) 91:917–25.
Chiueh CC. Neuroprotective properties of nitric oxide. Ann N Y Acad Sci.
(1999) 890:301-11.
Chung KK, Thomas B, Li X, Pletnikova O, Troncoso JC, Marsh L, Dawson
VL, Dawson TM. S-nitrosylation of parkin regulates ubiquitination and
compromises

parkin's

protective

function.

Science

(2004)

28:304(5675);1328-31.
Clarren SK, and Smith DW. The fetal alcohol syndrome. N Engl J Med.
(1978) 298:19;1063-7.
Climent E, Pascual M, Renau-Piqueras J, Guerri C. Ethanol exposure
enhances cell death in the developing cerebral cortex: role of brain-derived
neurotrophic factor and its signaling pathways. J Neurosci Res. (2002)
68:213–225.
Collen, D. The plasminogen (fibrinolytic) system. Thromb Haemost (1999)
82: 259–70.
Conrad CD, Galea LA, Kuroda Y, McEwen BS. Chronic stress impairs rat
spatial memory on the Y maze, and this effect is blocked by tianeptine
pretreatment. Behavioral neuroscience (1996) 110(6):1321-1334.

124

Corlew R, Wang Y, Ghermazien H, Erisir A, and Philpot BD.
Developmental Switch in the Contribution of Presynaptic and Postsynaptic
NMDA Receptors to Long-Term Depression. J. Neurosci. (2007) 27, 98359845.
Cook SC and Wellman CL. Chronic stress alters dendritic morphology in rat
medial prefrontal cortex, J. Neurobiol. (2004), 60: 236–248.
Christopherson KS, Hillier BJ, Lim WA, Bredt DS. PSD-95 assembles a
ternary complex with the N-methyl-D-aspartic acid receptor and a bivalent
neuronal NO synthase PDZ domain. J Biol Chem. (1999) 24;274(39):2746773.
Cull-Candy S, Brickley S, Farrant M. NMDA receptor subunits: diversity,
development and disease. Curr Opin Neurobiol. (2001) 11(3):327-35.
Dikranian K, Ishimaru MJ, Tenkova T, Labruyere J, Qin YQ, Ikonomidou
C, Olney JW. Apoptosis in the in vivo mammalian forebrain. Neurobiol Dis.
(2001) 8(3):359-79.
Dikranian K, Qin YQ, Labruyere J, Nemmers B, Olney JW. Ethanol-induced
neuroapoptosis in the developing rodent cerebellum and related brain stem
structures. Brain Res Dev Brain Res. (2005) 155(1):1-13.
Dobbing J and Sands J. Comparative aspects of the brain growth spurt. Early
Hum Dev. (1979) 1:79-83.

125

Duvarci and Pare D. Glucocorticoids enhance the excitability of principal
basolateral amygdala neurons, J. Neurosci. (2007) 27:4482–4491.
Famy C, Streissguth AP, Unis AS. Mental Illness in Adults With Fetal
Alcohol Syndrome or Fetal Alcohol Effects. Am. J. Psychiatr. 1998 155552.
Fiorucci S, Mencarelli A, Palazzetti B, Del Soldato P, Morelli A, Ignarro LJ.
An NO derivative of ursodeoxycholic acid protects against Fas-mediated
liver injury by inhibiting caspase activity. Proc Natl Acad Sci USA (2001)
98(5):2652-7.
Follesa P, Ticku MK. Chronic ethanol treatment differentially regulates
NMDA receptor subunit mRNA expression in rat brain. Brain Res Mol
Brain Res. (1995) 1:99-106.
Frey U, Müller M, Kuhl D A different form of long-lasting potentiation
revealed in tissue plasminogen activator mutant mice. J Neurosci (1996)
16:2057-2063.
Friedman GC, Seeds NW. Tissue plasminogen activator mRNA expression
in granule neurons coincides with their migration in the developing
cerebellum. J Comp Neurol. (1995) 360(4):658-70.
Garofalo, L; Ribeiro-da-Silva, A; Cuello, AC. Nerve growth factor-induced
synaptogenesis and hypertrophy of cortical cholinergic terminals. Proc Natl
Acad Sci USA (1992) 89(7):2639–2643.
126

Garthwaite J, Charles SL, Chess-Williams R. Endothelium-derived relaxing
factor release on activation of NMDA receptors suggests role as intercellular
messenger in the brain. Nature (1988) 336(6197):385-8.
Garthwaite J, Garthwaite G, Palmer RM, Moncada S. NMDA receptor
activation induces nitric oxide synthesis from arginine in rat brain slices. Eur
J Pharmacol. (1989) 172(4-5):413-6.
Ghiani CA, Beltran-Parrazal L, Sforza DM, Malvar JS, Seksenyan A, Cole
R, Smith DJ, Charles A, Ferchmin PA, de Vellis J. Genetic program of
neuronal differentiation and growth induced by specific activation of NMDA
receptors. Neurochem Res. (2007) 32(2):363-76.
Giasson, BI; Duda, JE; Murray, IV; Chen, Q; Souza, JM; Hurtig, HI;
Ischiropoulos, H; Trojanowski, JQ; Lee, VM. Oxidative damage linked to
neurodegeneration by selective alpha-synuclein nitration in synucleinopathy
lesions. Science (2000) 290(5493):985–989.
Goodlett CR and West JR. Maternal Substance Abuse and the Developing
Nervous System, I. Zagon and T. Slotkin, Eds. (Academic Press, San Diego,
CA, 1992), pp. 45-75.
Gould E, Tanapat P, McEwen BS, Flugge G, and Fuchs E. Proliferation of
granule cell precursors in the dentate gyrus of adult monkeys is diminished
by stress, Proc. Natl. Acad. Sci. USA (1998) 95:3168–3171.

127

Grant KA, Valverius P, Hudspith M, Tabakoff B. Ethanol withdrawal
seizures and the NMDA receptor complex. Eur J Pharmacol. (1990)
176(3):289-96.
Grenett HE, Aikens ML, Tabengwa EM, Davis GC, Booyse FM. Ethanol
downregulates transcription of the PAI-1 gene in cultured human endothelial
cells. Thromb Res. (2000) 97(4):247-55.
Groc L, Heine M, Cousins SL, Stephenson FA, Lounis B, Cognet L,
Choquet D. NMDA receptor surface mobility depends on NR2A-2B
subunits. Proc Natl Acad Sci U S A (2006) 103(49):18769-74.
Gualandris A, Jones TE, Strickland S, Tsirka SE. Membrane depolarization
induces calcium-dependent secretion of tissue plasminogen activator. J
Neurosci. (1996) 16:2220–5.
Guizzetti M, Moore NH, Giordano G, Costa LG. Modulation of
neuritogenesis by astrocyte muscarinic receptors. J Biol Chem. (2008)
283(46):31884-97.
Harris BT, Costa E, Grayson DR. Exposure of neuronal cultures to K+
depolarization or to N-methyl-D-aspartate increases the transcription of
genes encoding the alpha 1 and alpha 5 GABAA receptor subunits. Brain
Res Mol Brain Res. (1995) 28(2):338-42.

128

Hardingham GE, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose
synaptic NMDARs by triggering CREB shut-off and cell death pathways.
Nat Neurosci. (2002) 5(5):405-14.
Heaton MB, Paiva M, Swanson DJ, Walker DW. Responsiveness of cultured
septal and hippocampal neurons to ethanol and neurotrophic substances. J
Neurosci Res. (1994) 39(3):305-18.
Heaton MB, Paiva M, Madorsky I, Shaw G. Ethanol effects on neonatal rat
cortex: comparative analyses of neurotrophic factors, apoptosis-related
proteins, and oxidative processes during vulnerable and resistant periods.
Brain Res Dev Brain Res. (2003) 145(2):249-62.
Heaton MB, Paiva M, Madorsky I, Siler-Marsiglio K, Shaw G. Effect of bax
deletion on ethanol sensitivity in the neonatal rat cerebellum. J Neurobiol.
(2006) 66(1):95-101.
Heck N, Golbs A, Riedemann T, Sun JJ, Lessmann V, Luhmann HJ.
Activity-dependent regulation of neuronal apoptosis in neonatal mouse
cerebral cortex. Cereb Cortex (2008) 18(6):1335-49.
Hidalgo, 2003. A. Hidalgo, Neuron–glia interactions during axon guidance.
Transactions of the Biochemical Society 31 (2003), pp. 50–55.
Hino H, Akiyama H, Iseki E, Kato M, Kondo H, Ikeda K, Kosaka K
Immunohistochemical localization of plasminogen activator inhibitor-1 in
rat, human brain tissues. Neurosci Lett (2001) 297:105-108.
129

Hoffman WH, Haberly LB. Bursting induces persistent all-or-none EPSPs
by an NMDA-dependent process in piriform cortex. J Neurosci. (1989)
9(1):206-15.
Huang Y-Y, Bach ME, Lipp H-P, Zhuo M, Wolfer DP, Hawkins RD,
Schoonjans L, Kandel ER, Godfraind J-M, Mulligan R, Collen D, Carmeliet
P. Mice lacking the gene encoding tissue-type plasminogen activator show a
selective interference with late-phase long-term potentiation in both Schaffer
collateral and mossy fiber pathways. Proc Natl Acad Sci USA (1996)
93:8699-8704.
Huang EJ and Reichardt LF. Annu. Rev. Neurosci. (2001) 24:677–736.
Ieraci A, Herrera DG. Nicotinamide protects against ethanol-induced
apoptotic neurodegeneration in the developing mouse brain. PLoS Med.
(2006) 3(4):e101.
Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vöckler J, Dikranian K,
Tenkova TI, Stefovska V, Turski L, Olney JW. Blockade of NMDA
receptors and apoptotic neurodegeneration in the developing brain. Science
(1999) 283(5398):70-4.
Ikonomidou C, Bittigau P, Ishimaru MJ, Wozniak DF, Koch C, Genz K,
Price MT, Stefovska V, Hörster F, Tenkova T, Dikranian K, and Olney JW.
Ethanol-Induced Apoptotic Neurodegeneration and Fetal Alcohol Syndrome.
Science (2000) 287:5455; 1056-60.

130

Indyk JA, Chen ZL, Tsirka SE, Strickland S. Laminin chain expression
suggests that laminin-10 is a major isoform in the mouse hippocampus and
is degraded by the tissue plasminogen activator/plasmin protease cascade
during excitotoxic injury. Neuroscience (2003) 116:359–71.
Jones KL and Smith DW. Recognition of the fetal alcohol syndrome in early
infancy. Lancet (1973) 2(7836):999-1001.
Jones KL, Smith DW, Ulleland CN, Streissguth P. Pattern of malformation
in offspring of chronic alcoholic mothers. Lancet (1973) 1:7815;1267-71.
Kang YC, Kim PK, Choi BM, Chung HT, Ha KS, Kwon YG, Kim YM.
Regulation of programmed cell death in neuronal cells by nitric oxide. In
Vivo (2004) 18(3):367-76.
Karaçay B, Li G, Pantazis NJ, Bonthius DJ. Stimulation of the cAMP
pathway protects cultured cerebellar granule neurons against alcoholinduced cell death by activating the neuronal nitric oxide synthase (nNOS)
gene. Brain Res (2007) 1143:34-45.
Katz, L. C. and Shatz, C. J. Synaptic activity and the construction of cortical
circuits. Science (1996) 274,1133 -1138.
Kerns KA, Don A, Mateer CA, Streissguth AP. Cognitive deficits in nonretarded adults with fetal alcohol syndrome. J. Learn. Disab. 1997. 30, 685

131

Keynes, RG; Garthwaite, J. Nitric oxide and its role in ischaemic brain
injury. Curr Mol Med. (2004) 4:179–191.
Kim SJ, Ju JW, Oh CD, Yoon YM, Song WK, Kim JH, Yoo YJ, Bang OS,
Kang SS, Chun JS. ERK-1/2 and p38 kinase oppositely regulate nitric oxideinduced apoptosis of chondrocytes in association with p53, caspase-3, and
differentiation status. J Biol Chem. (2002) 277(2):1332-9.
Kim JH, Lee HK, Takamiya K, Huganir RL The role of synaptic GTPaseactivating protein in neuronal development and synaptic plasticity. J
Neurosci (2003) 23:1119–1124.
Kimura M, Soeda S, Oda M, Ochiai T, Kihara T, Ono N, Shimeno H.
Release of plasminogen activator inhibitor-1 from human astrocytes is
regulated by intracellular ceramide. J Neurosci Res. (2000) 62(6):781-8.
Komiyama NH, Watabe AM, Carlisle HJ, Porter K, Charlesworth P, Monti
J, Strathdee DJ, O'Carroll CM, Martin SJ, Morris RG, O'Dell TJ, Grant SG.
SynGAP regulates ERK/MAPK signaling, synaptic plasticity, and learning
in the complex with postsynaptic density 95 and NMDA receptor. J
Neurosci (2002) 22:9721–9732.
Komuro, H. and Rakic, O. Orchestration of neuronal migration by activity of
ion channels, neurotransmitter receptors, and intracellular Ca2+ fluctuations.
J. Neurobiol. (1998) 37:110 -130.

132

Kornau HC, Seeburg PH, Kennedy MB. Interaction of ion channels and
receptors with PDZ domain proteins. Curr Opin Neurobiol. (1997) 7(3):36873.
Krystosek A, Seeds NW. Plasminogen activator release at the neuronal
growth cone. Science (1981) 213(4515):1532-4.
Kutsuwada T, Sakimura K, Manabe T, Takayama C, Katakura N, Kushiya
E, Natsume R, Watanabe M, Inoue Y, Yagi T, Aizawa S, Arakawa M,
Takahashi T, Nakamura Y, Mori H, Mishina M. Impairment of suckling
response, trigeminal neuronal pattern formation, and hippocampal LTD in
NMDA receptor epsilon 2 subunit mutant mice. Neuron (1996) 16(2):33344.
Lalli G and Hall A. Ral GTPases regulate neurite branching through GAP43 and the exocyst complex. J Cell Bio (2005) 171(5):857-869.
Lavezzari G, McCallum J, Dewey CM, and Roche KW. Subunit-Specific
Regulation of NMDA Receptor Endocytosis. J Neurosci. (2004)
24(28):6383-9.
Lawrence DA, Strandberg L, Ericson J, Ny T. Structure-function studies of
the SERPIN plasminogen activator inhibitor type 1. Analysis of chimeric
strained loop mutants. J Biol Chem. (1990) 265(33):20293-301.

133

Lee S, Liu L, Wang Y, Sheng M. Clathrin Adaptor AP2 and NSF Interact
with Overlapping Sites of GluR2 and Play Distinct Roles in AMPA
Receptor Trafficking and Hippocampal LTD. Neuron (2002) 36(4): 661–
674.
Lessmann V, Gottmann K, Malcangio M Neurotrophin secretion: current
facts and future prospects. Prog Neurobiol (2003) 69:341–374.
Lipton SA, Stamler JS. Actions of redox-related congeners of nitric oxide at
the NMDA receptor. Neuropharmacology. (1994) 33(11):1229-33.
Liu Y, Wong TP, Aarts M, Rooyakkers A, Liu L, Lai TW, Wu DC, Lu J,
Tymianski M, Craig AM, Wang YT. NMDA receptor subunits have
differential roles in mediating excitotoxic neuronal death both in vitro and in
vivo. J Neurosci. (2007) 27(11):2846-57.
Liu XB, Murray KD, Jones EG. Switching of NMDA receptor 2A and 2B
subunits at thalamic and cortical synapses during early postnatal
development. J Neurosci. (2004) 24(40):8885-95.
Lovinger DM, White G, Weight FF. Ethanol inhibits NMDA-activated ion
current in hippocampal neurons. Science (1989) 243:1721-1724.
Luikart BW, Parada LF. Receptor tyrosine kinase B-mediated excitatory
synaptogenesis. Prog Brain Res. (2006)157:15-24.

134

Maas JW, Indacochea RA, Muglia LM, Tran TT, Vogt SK, West T, Benz A,
Shute AA, Holtzman DM, Mennerick S, Olney JW, Muglia LJ. Calciumstimulated adenylyl cyclases modulate ethanol-induced neurodegeneration in
the neonatal brain. J Neurosci. (2005) 25(9): 2376-85.
Madani R, Hulo S, Toni N, Madani H, Steimer T, Muller D, Vassali J-D
Enhanced hippocampal long-term potentiation and learning by increased
neuronal expression of tissue-type plasminogen activator in transgenic mice.
EMBO J (1999)18:3007-3012.
Masood K, Wu C, Brauneis U, Weight FF. Differential ethanol sensitivity of
recombinant N-methyl-D-aspartate receptor subunits. Mol Pharmacol.
(1994) 45(2):324-9.
Masos, T; Miskin, R. mRNAs encoding urokinase-type plasminogen
activator and plasminogen activator inhibitor-1 are elevated in the mouse
brain following kainate-mediated excitation. Brain Res Mol Brain Res.
(1997) 47:157–69.
Mattson SN, Riley EP, Sowell ER, Jernigan TL, Sobel DF, Jones KL. A
Decrease in the Size of the Basal Ganglia in Children with Fetal Alcohol
Syndrome. Alcohol Clin Exp Res. (1996) 20(6):1088-93.
Matys, T; Strickland, S. Tissue plasminogen activator and NMDA receptor
cleavage. Nat Med (2003) 9:371–2.

135

Matys T, Pawlak R, Matys E, Pavlides C, McEwen BS, Strickland S. Tissue
plasminogen activator promotes the effects of corticotropin-releasing factor
on the amygdala and anxiety-like behavior. Proc Natl Acad Sci U S A.
(2004) 101(46):16345-50.
McEwen, B. S. Stress and hippocampal plasticity. Annu. Rev. Neurosci.
(1999) 22:105-122.
McEwen BS. Central effects of stress hormones in health and disease:
Understanding the protective and damaging effects of stress and stress
mediators. Eur J Pharmacol. (2008) 583(2-3):174-85.
McLaughlin KJ, Gomez JL, Baran SE and Conrad CE. The effects of
chronic stress on hippocampal morphology and function: An evaluation of
chronic restraint paradigms. Brain Research (2007) 1161: 56-64.
Melchor JP, Strickland S. Tissue plasminogen activator in central nervous
system physiology and pathology. Thromb Haemost. (2005) 93(4):655-60.
Mennerick S, Zorumski CF. Neural activity and survival in the developing
nervous system. Mol Neurobiol. (2000) 22(1-3):41-54.
Mirshahi T, Woodward JJ. Ethanol sensitivity of heteromeric NMDA
receptors: effects of subunit assembly, glycine and NMDAR1 Mg(2+)insensitive mutants. Neuropharmacology. (1995) 34(3):347-55.

136

Nagappan G, Lu B. Activity-dependent modulation of the BDNF receptor
TrkB: mechanisms and implications. Trends Neurosci. (2005) 28(9):464-71.
Neuhoff H, Roeper J, Schweizer M. Activity-dependent formation of
perforated synapses in cultured hippocampal neurons. Eur J Neurosci
(1999)11:4241-4250.
Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, MacKenzie ET, Vivien
D, Buisson A. The proteolytic activity of tissue-plasminogen activator
enhances NMDA receptor-mediated signaling. Nat Med. (2001) 7:59–64.
Norris EH, Strickland S. Modulation of NR2B-regulated contextual fear in
the hippocampus by the tissue plasminogen activator system. Proc Natl Acad
Sci U S A. (2007) 104(33):13473-8.
Olney JW, Ishimaru MJ, Bittigau P, Ikonomidou C. Ethanol-induced
apoptotic neurodegeneration in the developing brain. Apoptosis (2000)
5(6):515-21.
Olney JW, Wozniak DF, Jevtovic-Todorovic V, Farber NB, Bittigau P,
Ikonomidou C. Drug-induced apoptotic neurodegeneration in the developing
brain. Brain Pathol. (2002) 12(4):488-98.
Olney JW, Wozniak DF, Jevtovic-Todorovic V, Farber NB, Bittigau P,
Ikonomidou C. Glutamate and GABA receptor dysfunction in the fetal
alcohol syndrome. Neurotox Res. (2002) 4(4):315-25.

137

Olson ST, Swanson R, Day D, Verhamme I, Kvassman J, Shore JD.
Resolution of Michaelis complex, acylation, and conformational change
steps in the reactions of the serpin, plasminogen activator inhibitor.
Biochemistry (2001) 40(39):11742-56.
Pang PT, Teng HK, Zaitsev E, Woo NT, Sakata K, Zhen S, Teng KK, Yung
WH, Hempstead BL, Lu B. Cleavage of proBDNF by tPA/plasmin is
essential for long-term hippocampal plasticity.

Science

(2004)

306(5695):487-91.
Pantazis NJ, West JR, Dai D. The nitric oxide-cyclic GMP pathway plays an
essential role in both promoting cell survival of cerebellar granule cells in
culture and protecting the cells against ethanol neurotoxicity. J Neurochem.
(1998). 70(5):1826-38.
Pawlak R, Magarinos AM, Melchor J, McEwen B, Strickland S. Tissue
plasminogen activator in the amygdala is critical for stress-induced anxietylike behavior. Nat Neurosci. (2003) 6(2):168-74.
Pawlak, R, Melchor JP, Matys T, Skrzypiec AE, Strickland S. Ethanolwithdrawal seizures are controlled by tissue plasminogen activator via
modulation of NR2B-containing NMDA receptors. Proc Natl Acad Sci U S
A. (2005) 102:443–8.
Paul J, Strickland S, Melchor JP. Fibrin deposition accelerates neurovascular
damage and neuroinflammation in mouse models of Alzheimer's disease. J
Exp Med. (2007) 204(8):1999-2008.
138

Pawlak R, Rao BS, Melchor JP, Chattarji S, McEwen B, Strickland S.
Tissue plasminogen activator and plasminogen mediate stress-induced
decline of neuronal and cognitive functions in the mouse hippocampus. Proc
Natl Acad Sci U S A (2005) 102(50):18201-6.
Penn, A. A., Riquelme, P. A., Feller, M. B. and Shatz, C. J. Competition in
retinogeniculate pattering driven by spontaneous activity. Science (1998)
279:2108 -2112.
Perez-Otano and Ehlers. Homeostatic plasticity and NMDA receptor
trafficking.Trends Neurosci. (2005) 28(5):229-38.
Porter K, Komiyama NH, Vitalis T, Kind PC, Grant SG. Differential
expression of two NMDA receptor interacting proteins, PSD-95 andSynGAP
during mouse development. Eur J Neurosci. (2005) 21(2):351-62.
Prybylowski K, Chang K, Sans N, Kan L, Vicini S, Wenthold RJ. The
synaptic localization of NR2B-containing NMDA receptors is controlled by
interactions with PDZ proteins and AP-2. Neuron (2005) 47(6):845-57.
Risau W. Molecular biology of blood-brain barrier ontogenesis and function.
Acta Neurochir. (1994) 60 suppl:109-112.
Rivkin MJ, Davis PE, Lemaster JL, Cabral HJ, Warfield SK, Mulkern RV,
Robson CD, Rose-Jacobs R, and Frank DA. Volumetric MRI Study of Brain
in Children With Intrauterine Exposure to Cocaine, Alcohol, Tobacco, and
Marijuana. Pediatrics (2008) 121: 741-750.
139

Roche KW, Standley S, McCallum J, Dune Ly C, Ehlers MD, Wenthold RJ.
Molecular determinants of NMDA receptor internalization. Nat Neurosci.
(2001) 4(8):794-802.
Qian Z, Gilbert ME, Colicos MA, Kandel ER, Kuhl D. Tissue-plasminogen
activator is induced as an immediate-early gene during seizure, kindling and
long-term potentiation. Nature (1993) 361:453–7.
Schmued LC, Hopkins KJ. Fluoro-Jade B: a high affinity fluorescent marker
for the localization of neuronal degeneration. Brain Res. (2000) 874(2):12330.
Seeds NW, Williams BL, Bickford PC. Tissue plasminogen activator
induction in Purkinje neurons after cerebellar motor learning. Science.
(1995) 270:1992–4.
Sharp RE, Chapman SK. Mechanisms for regulating electron transfer in
multi-centre redox proteins. Biochim Biophys Acta. (1999) 1432(2):143-58.
Sheng M, Cummings J, Roldan LA, Jan YN, Jan LY. Changing subunit
composition of heteromeric NMDA receptors during development of rat
cortex. Nature (1994) 368(6467):144-7.
Sheng M, Kim MJ. Postsynaptic Signaling and Plasticity Mechanisms.
Science (2002) 298:5594, 776 – 780.

140

Shimazaki K, Ishida A & Kawai N. Increase in bcl-2 oncoprotein and the
tolerance to ischemia-induced neuronal death in the gerbil hippocampus.
Neurosci Res (1994)20: 95−99.
Spitzer NC, Lautermilch NJ, Smith RD, and Gomez TM. Coding of neuronal
differentiation by calcium transients. BioEssays (2000) 22,811 -817.
Skrzypiec A, Maiya R, Pawlak R, Strickland S. Plasmin-mediated
degradation of laminin γ-1 is critical for neurodegeneration after ethanol
withdrawal, a model of delirium tremens. Submitted (2008).
Snell LD, Nunley KR, Lickteig RL, Browning MD, Tabakoff B, Hoffman
PL. Regional and subunit specific changes in NMDA receptor mRNA and
immunoreactivity in mouse brain following chronic ethanol ingestion. Brain
Res Mol Brain Res. (1996) 40(1):71-8.
Soeda S, Oda M, Ochiai T, Shimeno H. Deficient release of plasminogen
activator inhibitor-1 from astrocytes triggers apoptosis in neuronal cells.
Brain Res Mol Brain Res. (2001) 91(1-2):96-103.
Stellwagen D, and Shatz CJ. An instructive role for retinal waves in the
development of retinogeniculate connectivity. Neuron (2002) 33:357 -367.
Sulik KK, Johnston MC, Webb MA. Fetal alcohol syndrome: embryogenesis
in a mouse model. Science (1981) 214, 936.

141

Suzuki S, Kiyosue K, Hazama S, Ogura A, Kashihara M, Hara T, Koshimizu
H, Kojima M. Brain-derived neurotrophic factor regulates cholesterol
metabolism for synapse development. J Neurosci. (2007) 27(24):6417-27.
Swayze VW , Johnson VP, Hanson JW, Piven J, Sato J, Giedd JN, Mosnik D,
and Andreasen NC. Magnetic Resonance Imaging of Brain Anomalies in
Fetal Alcohol Syndrome. Pediatrics (1997) 99:232.
Toscano CD, Kingsley PJ, Marnett LJ, Bosetti F. NMDA-induced seizure
intensity is enhanced in COX-2 deficient mice. Neurotoxicology (2008)
29(6):1114-20.
Tovar KR, Sprouffske K, Westbrook GL. Fast NMDA receptor-mediated
synaptic currents in neurons from mice lacking the epsilon2 (NR2B) subunit.
J Neurophysiol. (2000) 83(1):616-20.
Tovar KR and Westbrook GL. Mobile NMDA Receptors at Hippocampal
Synapses. Neuron (2002) 34(2):255-64.
Tsirka SE, Gualandris A, Amaral DG, Strickland S. Excitotoxin-induced
neuronal degeneration and seizure are mediated by tissue plasminogen
activator. Nature (1995) 377:340–4.
Tsirka SE, Rogove AD, Strickland S. Neuronal cell death and tPA. Nature
(1996) 384(6605):123-4.

142

Uehara T, Nakamura T, Yao D, Shi ZQ, Gu Z, Ma Y, Masliah E, Nomura Y,
Lipton SA. S-nitrosylated protein-disulphide isomerase links protein
misfolding to neurodegeneration. Nature. 2006 May 25;441(7092):513-7.
Wang X, Lee SR, Arai K, Lee SR, Tsuji K, Rebeck GW, Lo EH.
Lipoprotein receptor-mediated induction of matrix metalloproteinase by
tissue plasminogen activator. Nat Med. (2003) 9:1313–7.
Waxman EA, Lynch DR. N-methyl-D-aspartate receptor subtype mediated
bidirectional control of p38 mitogen-activated protein kinase. J Biol Chem.
(2005) 280(32):29322-33.
West JR. Fetal alcohol-induced brain damage and the problem of
determining temporal vulnerability: a review. Alcohol Drug Research (1987)
7:423.
Widmer F and Caroni P. Phosphorylation-site mutagenesis of the growthassociated protein GAP- 43 modulates its effects on cell spreading and
morphology. The Journal of Cell Biology (1993) 120: 503-512.
Wood GE, Young LT, Reagan LP, McEwen BS. Acute and chronic restraint
stress alter the incidence of social conflict in male rats. Horm Behav. (2003)
43(1):205-13.
Xu J, Ling EA. Studies of the ultrastructure and permeability of the bloodbrain barrier in the developing corpus callosum in postnatal rat brain using
electron dense tracers. J Anat. (1993)184:227-237.
143

Yaka R, Phamluong K, Ron D. Scaffolding of Fyn kinase to the NMDA
receptor determines brain region sensitivity to ethanol. J Neurosci. (2003)
23(9):3623-32.
Yang J, Woodhall GL, Jones RSG. Tonic Facilitation of Glutamate Release
by Presynaptic NR2B-Containing NMDA Receptors Is Increased in the
Entorhinal Cortex of Chronically Epileptic Rats. The Journal of
Neuroscience (2006) 26(2):406-410.
Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, Lawrence
DA. Tissue-type plasminogen activator induces opening of the blood-brain
barrier via the LDL receptor-related protein. J Clin Invest. (2003) 112:1533–
40.
Young C, Klocke J, Tenkova T, Choi J, Labruyere J, Qin Y-Q, Holtzman
DM, Roth KA, and Olney JW. Ethanol-induced neuronal apoptosis in vivo
requires BAX in the developing mouse brain. Cell Death and Differentiation
(2003) 10: 1148–1155.
Young C, Jevtovic-Todorovic V, Qin YQ, Tenkova T, Wang H, Labruyere J,
Olney JW. Potential of ketamine and midazolam, individually or in
combination, to induce apoptotic neurodegeneration in the infant mouse
brain. Br J Pharmacol. (2005) 146(2):189-97.
Yu XM, Askalan R, Keil II GJ, Salter MW. NMDA Channel Regulation by
Channel-Associated Protein Tyrosine Kinase Src. Science (1997) 275(5300)
674 – 678.
144

Yun HY, Gonzalez-Zulueta M, Dawson VL, Dawson TM. Nitric oxide
mediates N-methyl-D-aspartate receptor-induced activation of p21ras. Proc
Natl Acad Sci U S A. (1998) 95(10):5773-8.
Zhang S, Edelmann L, Liu J, Crandall JE, Morabito MA. Cdk5 regulates the
phosphorylation of tyrosine 1472 NR2B and the surface expression of
NMDA receptors. J Neurosci. (2008) 28(2):415-24.
Zhang J, Zhang D, McQuade JS, Behbehani M, Tsien JZ, Xu M. c-fos
regulates neuronal excitability and survival. Nat Genet. (2002) 30(4):41620.
Zhou M, Baudry M. Developmental changes in NMDA neurotoxicity reflect
developmental changes in subunit composition of NMDA receptors. J
Neurosci. (2006) 26(11):2956-63.

145

